0001569329 Youngevity International,
Inc. false --12-31 Q1 2020 0.001 0.001 5,000,000 5,000,000 8 8
161,135 161,135 161,135 161,135 5 5 0 0 129,332 129,332 9.75 9.75
590,273 590,273 578,898 578,898 14,877 0.001 0.001 50,000,000
50,000,000 30,712,432 30,712,432 30,274,601 30,274,601 469 500,000
8,707,000 7,871,000 4,700,000 3 76,924 116,655 3 0 0 25,000 0 0 0
8,707,000 7,871,000 1,649,000 5,000,000 4 4 4 2 2,000,000 5 6.00
6.00 8.00 8.00 5 25,000 3 3 5 3 448,420 4 631,579 4 4 150,000
161,135 0.1 6,098 4 3 3 8,707,000 7,871,000 2 5 25 75 Assets held
for sale at March 31, 2020 consisted of approximately $1,053,000 in
land and $443,000 in building related to the commercial hemp
segment. (See Note 13) Finance lease right-of-use assets are
recorded within property and equipment, net of accumulated
amortization of approximately $1,548,000 and $1,367,000 at March
31, 2020 and December 31, 2019, respectively.
00015693292020-01-012020-03-31 xbrli:shares 00015693292022-06-17
thunderdome:item iso4217:USD 00015693292020-03-31
00015693292019-12-31
0001569329ygyi:NotesPayableExcludingConvertibleNotesPayableMember2020-03-31
0001569329ygyi:NotesPayableExcludingConvertibleNotesPayableMember2019-12-31
iso4217:USDxbrli:shares xbrli:pure
0001569329ygyi:SeriesAConvertiblePreferredStockMember2020-01-012020-03-31
0001569329ygyi:SeriesAConvertiblePreferredStockMember2019-01-012019-12-31
0001569329ygyi:SeriesAConvertiblePreferredStockMember2020-03-31
0001569329ygyi:SeriesAConvertiblePreferredStockMember2019-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2020-01-012020-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2019-01-012019-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2020-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2020-01-012020-03-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-01-012019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2020-03-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-12-31
00015693292019-01-012019-03-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2019-12-31
0001569329us-gaap:CommonStockMember2019-12-31
0001569329us-gaap:AdditionalPaidInCapitalMember2019-12-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31
0001569329us-gaap:RetainedEarningsMember2019-12-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-03-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-03-31
0001569329us-gaap:CommonStockMember2020-01-012020-03-31
0001569329us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-31
0001569329us-gaap:RetainedEarningsMember2020-01-012020-03-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-03-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-03-31
0001569329us-gaap:CommonStockMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-03-31
0001569329us-gaap:AdditionalPaidInCapitalMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-03-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-03-31
0001569329us-gaap:RetainedEarningsMemberygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-03-31
0001569329ygyi:UnderwrittenRegisteredPublicOfferingMember2020-01-012020-03-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-03-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:PreferredStockMember2020-03-31
0001569329us-gaap:CommonStockMember2020-03-31
0001569329us-gaap:AdditionalPaidInCapitalMember2020-03-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-31
0001569329us-gaap:RetainedEarningsMember2020-03-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2018-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2018-12-31
0001569329us-gaap:CommonStockMember2018-12-31
0001569329us-gaap:AdditionalPaidInCapitalMember2018-12-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-31
0001569329us-gaap:RetainedEarningsMember2018-12-31
00015693292018-12-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-03-31
0001569329us-gaap:CommonStockMember2019-01-012019-03-31
0001569329us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-31
0001569329us-gaap:RetainedEarningsMember2019-01-012019-03-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2019-01-012019-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2019-01-012019-03-31
0001569329us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2019-01-012019-03-31
0001569329us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2019-01-012019-03-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:PrivatePlacementMember2019-01-012019-03-31
0001569329us-gaap:RetainedEarningsMemberus-gaap:PrivatePlacementMember2019-01-012019-03-31
0001569329us-gaap:PrivatePlacementMember2019-01-012019-03-31
0001569329us-gaap:LandMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-03-31
0001569329us-gaap:LandMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-03-31
0001569329us-gaap:LandMemberus-gaap:CommonStockMember2019-01-012019-03-31
0001569329us-gaap:LandMemberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-31
0001569329us-gaap:LandMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-31
0001569329us-gaap:LandMemberus-gaap:RetainedEarningsMember2019-01-012019-03-31
0001569329us-gaap:LandMember2019-01-012019-03-31
0001569329us-gaap:TrademarksMemberygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-03-31
0001569329us-gaap:TrademarksMemberygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-01-012019-03-31
0001569329us-gaap:TrademarksMemberus-gaap:CommonStockMember2019-01-012019-03-31
0001569329us-gaap:TrademarksMemberus-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-31
0001569329us-gaap:TrademarksMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-31
0001569329us-gaap:TrademarksMemberus-gaap:RetainedEarningsMember2019-01-012019-03-31
0001569329us-gaap:TrademarksMember2019-01-012019-03-31
0001569329ygyi:SeriesAConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-03-31
0001569329us-gaap:CommonStockMember2019-03-31
0001569329us-gaap:AdditionalPaidInCapitalMember2019-03-31
0001569329us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-31
0001569329us-gaap:RetainedEarningsMember2019-03-31
00015693292019-03-31
0001569329ygyi:PromissoryNotesMember2020-01-012020-03-31
0001569329ygyi:PromissoryNotesMember2019-01-012019-03-31
0001569329ygyi:PropertyAndEquipmentFundedByMortgageAgreementMember2020-01-012020-03-31
0001569329ygyi:PropertyAndEquipmentFundedByMortgageAgreementMember2019-01-012019-03-31
0001569329ygyi:PropertyAndEquipmentFundedByFinancingLeasingAgreementMember2020-01-012020-03-31
0001569329ygyi:PropertyAndEquipmentFundedByFinancingLeasingAgreementMember2019-01-012019-03-31
0001569329ygyi:CommonStockForPromissoryNoteFinancingMember2020-01-012020-03-31
0001569329ygyi:CommonStockForPromissoryNoteFinancingMember2019-01-012019-03-31
0001569329ygyi:StockForPropertyAndEquipmentMember2020-01-012020-03-31
0001569329ygyi:StockForPropertyAndEquipmentMember2019-01-012019-03-31
0001569329ygyi:StockForPurchaseOfIntangiblesMember2020-01-012020-03-31
0001569329ygyi:StockForPurchaseOfIntangiblesMember2019-01-012019-03-31
0001569329ygyi:StockForNoteReceivablesMember2020-01-012020-03-31
0001569329ygyi:StockForNoteReceivablesMember2019-01-012019-03-31
0001569329ygyi:StockIssuedForServiceMember2020-01-012020-03-31
0001569329ygyi:StockIssuedForServiceMember2019-01-012019-03-31
0001569329ygyi:StockInConnectionWithAcquisitionMember2020-01-012020-03-31
0001569329ygyi:StockInConnectionWithAcquisitionMember2019-01-012019-03-31
0001569329ygyi:DirectSellingSegmentMember2020-01-012020-03-31
0001569329ygyi:CommercialCoffeeSegmentMember2020-01-012020-03-31
0001569329ygyi:CommercialHempSegmentMember2020-01-012020-03-31
0001569329ygyi:DirectSellingSegmentMember2019-01-012019-03-31
0001569329ygyi:CommercialCoffeeSegmentMember2019-01-012019-03-31
0001569329ygyi:CommercialHempSegmentMember2019-01-012019-03-31
utr:acre 0001569329ygyi:CoffeePlantationMember2020-03-31
0001569329ygyi:DryprocessingFacilityMember2020-03-31
0001569329us-gaap:WarrantMember2020-01-012020-03-31
0001569329us-gaap:WarrantMember2019-01-012019-03-31
0001569329ygyi:PreferredStockConversionsMember2020-01-012020-03-31
0001569329ygyi:PreferredStockConversionsMember2019-01-012019-03-31
0001569329ygyi:PrincipalConversionOnConvertibleNotesMember2020-01-012020-03-31
0001569329ygyi:PrincipalConversionOnConvertibleNotesMember2019-01-012019-03-31
0001569329us-gaap:EmployeeStockOptionMember2020-01-012020-03-31
0001569329us-gaap:EmployeeStockOptionMember2019-01-012019-03-31
0001569329us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-31
0001569329us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-03-31
0001569329ygyi:BeneyouMembersrt:MaximumMember2019-11-012019-11-01
0001569329ygyi:BeneyouMember2019-11-012019-11-01
0001569329ygyi:BeneyouMember2019-11-01
0001569329ygyi:BeneyouMemberus-gaap:TrademarksAndTradeNamesMember2019-11-01
0001569329ygyi:BeneyouMemberygyi:DistributorOrganizationMember2019-11-01
0001569329ygyi:BeneyouMemberus-gaap:CustomerRelationshipsMember2019-11-01
0001569329ygyi:BeneyouMemberus-gaap:NoncompeteAgreementsMember2019-11-01
utr:Y
0001569329ygyi:BeneyouMemberus-gaap:TrademarksAndTradeNamesMember2019-11-012019-11-01
0001569329ygyi:BeneyouMemberygyi:DistributorOrganizationMember2019-11-012019-11-01
0001569329ygyi:BeneyouMemberus-gaap:CustomerRelationshipsMember2019-11-012019-11-01
0001569329ygyi:BeneyouMemberus-gaap:NoncompeteAgreementsMember2019-11-012019-11-01
0001569329ygyi:AepaWithKhrysosGlobalMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:CommonStockMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-02-132019-12-31
0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-12-312019-12-31
0001569329ygyi:AccruedExpensesMemberygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2020-03-31
0001569329ygyi:AccruedExpensesMemberygyi:AepaWithKhrysosGlobalMemberygyi:ConsiderationPayableInCashMember2019-12-31
0001569329ygyi:AepaWithKhrysosGlobalMemberygyi:ContingentConsiderationPayableInCashMember2019-02-122019-02-12
0001569329ygyi:KhrysosGlobalMember2019-02-12
0001569329ygyi:KhrysosGlobalMemberus-gaap:TrademarksAndTradeNamesMember2019-02-12
0001569329ygyi:KhrysosGlobalMemberus-gaap:CustomerRelationshipsMember2019-02-12
0001569329ygyi:KhrysosGlobalMemberus-gaap:NoncompeteAgreementsMember2019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMember2019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:TrademarksAndTradeNamesMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:CustomerRelationshipsMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMemberus-gaap:NoncompeteAgreementsMember2019-02-122019-02-12
0001569329ygyi:AepaWithKhrysosGlobalMember2019-12-31
0001569329ygyi:CLRMemberygyi:HhMember2020-01-012020-03-31
0001569329ygyi:CLRMemberygyi:HhExportMember2020-01-012020-03-31
0001569329ygyi:CLRMemberygyi:HhExportMember2019-01-012019-03-31
0001569329ygyi:CustomerRelatedRevenueReceivablesMemberygyi:CLRMemberygyi:HhExportMember2019-12-31
0001569329ygyi:CustomerRelatedRevenueReceivablesMemberygyi:CLRMemberygyi:HhExportMember2020-03-31
0001569329ygyi:CLRMemberygyi:HhExportMember2019-01-012019-12-31
0001569329ygyi:CLRMemberygyi:GreenCoffeeAcquisitionMemberygyi:HhMember2020-03-31
0001569329ygyi:CLRMemberygyi:BillingForFreightAndOtherChargesMemberygyi:HhMember2020-03-31
0001569329ygyi:CLRMemberygyi:MillOperationCostMemberygyi:HhMember2020-03-31
0001569329ygyi:CLRMemberygyi:GreenCoffeeSoldButNotDeliveredMemberygyi:HhMember2020-03-31
0001569329ygyi:NicaraguanAgencyMemberygyi:HhExportGroupMember2020-03-31
0001569329ygyi:CLRMemberygyi:HhExportMember2020-03-31
iso4217:USDutr:lb
0001569329ygyi:CLRMemberygyi:HhExportMember2018-12-31
0001569329ygyi:CLRMemberygyi:HhExportMember2019-03-31
0001569329ygyi:CLRMemberygyi:HhExportMember2019-03-012019-03-31
0001569329ygyi:CLRMemberygyi:HhExportMember2019-12-31
0001569329ygyi:CLRMemberygyi:MatagalpaPropertyMemberygyi:NicaraguanPartnerMember2019-01-31
0001569329ygyi:NicaraguanPartnerMember2019-01-31
0001569329ygyi:CLRMember2019-01-31
0001569329ygyi:HhExportMember2019-01-012019-01-31
0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2020-01-012020-03-31
0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2019-01-012019-03-31
0001569329ygyi:CLRMemberygyi:ConstructionOfMatagalpaMillProjectMember2019-01-012020-03-31
0001569329ygyi:CLRMemberygyi:OperatingEquipmentMember2019-01-012020-03-31
0001569329ygyi:ConstructionOfMatagalpaMillProjectMemberygyi:NicaraguanPartnerMember2019-01-012020-03-31
0001569329ygyi:HhExportMember2020-01-012020-03-31
0001569329ygyi:HhExportMember2019-01-012019-12-31
0001569329ygyi:CLRMemberygyi:HhExportMemberygyi:SharesIssuedForPurchaseConsiderationMember2019-01-012019-01-31
0001569329ygyi:CLRMemberygyi:HhExportMemberygyi:SharesIssuedForPurchaseConsiderationMember2019-01-31
0001569329ygyi:CLRMemberygyi:MrHernandezMember2017-05-31
0001569329ygyi:WvnpMember2020-01-012020-03-31
0001569329ygyi:WvnpMember2019-01-012019-03-31
0001569329ygyi:DistributorCommissionMemberygyi:RichardRentonMember2020-01-012020-03-31
0001569329ygyi:DistributorCommissionMemberygyi:RichardRentonMember2019-01-012019-03-31
0001569329ygyi:CreditNoteMemberygyi:MrGroverMember2020-03-31
0001569329ygyi:CreditNoteMemberygyi:MrGroverMember2019-12-31
0001569329ygyi:MrGroverMemberygyi:WarrantsWith2014ConvertibleNoteMember2019-07-012019-07-31
0001569329ygyi:MrGroverMemberygyi:WarrantsWith2014ConvertibleNoteMember2019-06-30
0001569329ygyi:MrGroverMemberygyi:WarrantsWith2014ConvertibleNoteMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:ConversionOf2014ConvertibleNoteIntoCommonStockMemberygyi:PaulSallwasserMember2020-01-012020-03-31
0001569329ygyi:WarrantsWith2014PrivatePlacementMemberygyi:PaulSallwasserMember2020-03-31
0001569329ygyi:ConversionOf2017ConvertiblePrivatePlacementNoteIntoCommonStockMemberygyi:PaulSallwasserMember2020-01-012020-03-31
0001569329ygyi:WarrantsWith2017PrivatePlacementMemberygyi:PaulSallwasserMember2020-03-31
0001569329ygyi:ConversionOf2017ConvertibleNoteIntoCommonStockMemberygyi:PaulSallwasserMember2020-01-012020-03-31
0001569329ygyi:WarrantsWith2017ConvertibleNoteMemberygyi:PaulSallwasserMember2020-03-31
0001569329ygyi:ConversionOf2017ConvertibleNoteIntoCommonStockMemberygyi:PaulSallwasserMember2018-03-012018-03-31
0001569329ygyi:WarrantsWith2017ConvertibleNoteMemberygyi:PaulSallwasserMember2018-03-31
0001569329ygyi:PaulSallwasserMember2019-08-012019-08-31
0001569329ygyi:PaulSallwasserMember2020-03-31
0001569329ygyi:PaulSallwasserMember2019-03-31
0001569329ygyi:MrDanielManglessMember2019-02-012019-02-28
0001569329ygyi:MrDanielManglessMember2019-02-28
0001569329ygyi:MrDanielManglessMember2019-06-012019-06-30
0001569329ygyi:MrDanielManglessMember2019-06-30
0001569329ygyi:MrDanielManglessMember2020-03-31
0001569329ygyi:MrDanielManglessMember2020-03-012020-03-31
0001569329ygyi:MrDanielManglessMembersrt:ScenarioForecastMember2021-04-012021-04-30
0001569329ygyi:JjeEquipmentMember2020-03-31
0001569329ygyi:JjeEquipmentMember2019-12-31
0001569329ygyi:YoungevityBeTheChangeFoundationMember2020-03-31
0001569329ygyi:YoungevityBeTheChangeFoundationMember2019-03-31
0001569329ygyi:CurrentLiabilitiesMemberygyi:YoungevityBeTheChangeFoundationMember2020-03-31
0001569329ygyi:CurrentLiabilitiesMemberygyi:YoungevityBeTheChangeFoundationMember2019-12-31
0001569329ygyi:YoungevityBeTheChangeFoundationMember2020-01-012020-03-31
0001569329ygyi:YoungevityBeTheChangeFoundationMember2019-01-012019-03-31
0001569329ygyi:PrivatePlacement2014Memberygyi:DanielBriskieAndMaidaBriskieMember2014-09-30
0001569329ygyi:PrivatePlacement2014Memberygyi:DanielBriskieAndMaidaBriskieMember2020-03-31
0001569329ygyi:PrivatePlacement2014Memberygyi:DanielBriskieAndMaidaBriskieMember2019-12-31
0001569329ygyi:PrivatePlacement2014Memberygyi:DouglasBriskieMember2014-08-31
0001569329ygyi:ProcessedGreenCoffeeMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-03-31
0001569329ygyi:ProcessedGreenCoffeeMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-03-31
0001569329ygyi:MillingAndProcessingServicesMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-03-31
0001569329ygyi:MillingAndProcessingServicesMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-03-31
0001569329ygyi:RoastedCoffeeAndOtherMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-03-31
0001569329ygyi:RoastedCoffeeAndOtherMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-03-31
0001569329ygyi:CustomerDepositsMember2020-03-31
0001569329ygyi:CustomerDepositsMember2019-12-31
0001569329ygyi:RewardsProgramMember2020-03-31
0001569329ygyi:HeritageMakersMember2020-03-31
0001569329ygyi:HeritageMakersMember2019-12-31
0001569329ygyi:ConventionAndDistributorEventsMember2020-03-31
0001569329ygyi:ConventionAndDistributorEventsMember2019-12-31
0001569329ygyi:CommercialCoffeeSegmentMember2020-03-31
0001569329ygyi:CommercialCoffeeSegmentMember2019-12-31
0001569329ygyi:CommercialHempSegmentMember2020-03-31
0001569329ygyi:CommercialHempSegmentMember2019-12-31
0001569329ygyi:HeritageMakersAndConventionAndDistributorEventsMember2020-01-012020-03-31
0001569329ygyi:HhExportMember2019-12-31
0001569329ygyi:HhExportMember2020-03-31
0001569329ygyi:HhExportMember2020-01-012020-03-31
0001569329ygyi:HhExportMember2019-01-012019-12-31
0001569329us-gaap:BuildingMember2020-03-31
0001569329us-gaap:BuildingMember2019-12-31
0001569329us-gaap:LeaseholdImprovementsMember2020-03-31
0001569329us-gaap:LeaseholdImprovementsMember2019-12-31
0001569329us-gaap:LandMember2020-03-31
0001569329us-gaap:LandMember2019-12-31
0001569329us-gaap:LandImprovementsMember2020-03-31
0001569329us-gaap:LandImprovementsMember2019-12-31
0001569329ygyi:ProducingCoffeeTreesMember2020-03-31
0001569329ygyi:ProducingCoffeeTreesMember2019-12-31
0001569329ygyi:ManufacturingEquipmentMember2020-03-31
0001569329ygyi:ManufacturingEquipmentMember2019-12-31
0001569329ygyi:FurnitureAndOtherEquipmentMember2020-03-31
0001569329ygyi:FurnitureAndOtherEquipmentMember2019-12-31
0001569329ygyi:ComputerSoftwareMember2020-03-31
0001569329ygyi:ComputerSoftwareMember2019-12-31
0001569329us-gaap:ComputerEquipmentMember2020-03-31
0001569329us-gaap:ComputerEquipmentMember2019-12-31
0001569329us-gaap:VehiclesMember2020-03-31
0001569329us-gaap:VehiclesMember2019-12-31
0001569329ygyi:AssetsHeldForSaleMember2020-03-31
0001569329ygyi:AssetsHeldForSaleMember2019-12-31
0001569329us-gaap:ConstructionInProgressMember2020-03-31
0001569329us-gaap:ConstructionInProgressMember2019-12-31
0001569329us-gaap:LandMember2020-03-31
0001569329us-gaap:ComputerEquipmentMemberygyi:CommercialHempSegmentMember2020-03-31
0001569329ygyi:SalesMarketingGeneralAndAdministrativeMember2020-01-012020-03-31
0001569329ygyi:SalesMarketingGeneralAndAdministrativeMember2019-01-012019-03-31
0001569329ygyi:DepreciationAndAmortizationMember2020-01-012020-03-31
0001569329ygyi:DepreciationAndAmortizationMember2019-01-012019-03-31
0001569329us-gaap:InterestExpenseMember2020-01-012020-03-31
0001569329us-gaap:InterestExpenseMember2019-01-012019-03-31
0001569329ygyi:DistributorOrganizationMember2020-03-31
0001569329ygyi:DistributorOrganizationMember2019-12-31
0001569329us-gaap:TrademarksAndTradeNamesMember2020-03-31
0001569329us-gaap:TrademarksAndTradeNamesMember2019-12-31
0001569329us-gaap:CustomerRelationshipsMember2020-03-31
0001569329us-gaap:CustomerRelationshipsMember2019-12-31
0001569329ygyi:InternallyDevelopedSoftwareMember2020-03-31
0001569329ygyi:InternallyDevelopedSoftwareMember2019-12-31
0001569329us-gaap:NoncompeteAgreementsMember2020-03-31
0001569329us-gaap:NoncompeteAgreementsMember2019-12-31
0001569329us-gaap:TrademarksMember2020-03-31
0001569329us-gaap:TrademarksMember2019-12-31
0001569329ygyi:DirectSellingSegmentMember2019-12-31
0001569329ygyi:DirectSellingSegmentMember2020-03-31
0001569329ygyi:CLRMemberygyi:CreditNoteMember2018-12-31
0001569329ygyi:CLRMemberygyi:CreditNoteMember2019-12-31
0001569329ygyi:CLRMemberygyi:CreditNoteMember2020-03-31
0001569329ygyi:WarrantWithCreditNotesOneMember2018-12-31
0001569329ygyi:WarrantsWithCreditNotesTwoMember2018-12-31
0001569329ygyi:CreditNoteMember2018-12-31
0001569329ygyi:CreditNotesWarrantsWithAdvisoryAgreementMember2018-12-31
0001569329ygyi:CreditNoteMember2020-01-012020-03-31
0001569329ygyi:CreditNoteMember2020-03-31
0001569329ygyi:CreditNoteMember2019-12-31
0001569329ygyi:PromissoryNotes2019Member2019-03-012019-03-31
0001569329ygyi:PromissoryNotes2019Member2019-03-31
0001569329ygyi:PromissoryNotes2019Member2020-03-31
0001569329ygyi:PromissoryNotes2019Member2019-12-31
0001569329ygyi:SharesInConnectionWithPromissoryNotes2019Member2019-03-012019-03-31
0001569329ygyi:WarrantsInConnectionWithPromissoryNotes2019Member2019-03-31
0001569329ygyi:ManglessNoteMember2020-03-31
0001569329ygyi:StockInConnectionWithManglessNoteMember2020-03-012020-03-31
0001569329ygyi:ManglessNoteMember2020-01-012020-03-31
0001569329srt:ScenarioForecastMemberygyi:StockInConnectionWithManglessNoteMember2021-04-012021-04-30
0001569329ygyi:BoswellMortgageNote2400Member2020-01-012020-03-31
0001569329ygyi:BoswellMortgageNote2400Memberus-gaap:PrimeRateMember2020-01-012020-03-31
0001569329ygyi:BoswellMortgageNote2400Member2020-03-312020-03-31
0001569329ygyi:BoswellMortgageNote2400Member2019-12-312019-12-31
0001569329ygyi:BoswellMortgageNote2400Member2020-03-31
0001569329ygyi:BoswellMortgageNote2400Member2019-12-31
0001569329ygyi:KhrysosMortgageNotesForPropertiesInClemontFloridaMember2020-03-31
0001569329ygyi:KhrysosMortgageNotesForPropertiesInMascotteFloridaMember2020-03-31
0001569329ygyi:KhrysosMortgageNotesForPropertiesInMascotteFloridaMember2019-12-31
0001569329ygyi:LandInGrovelandFloridaMember2019-02-28
0001569329ygyi:LandInGrovelandFloridaMember2019-02-012019-02-28
0001569329ygyi:MortgageWithLandAcquisitionInGrovelandFloridaMember2019-02-28
0001569329ygyi:MortgageWithLandAcquisitionInGrovelandFloridaMember2020-03-31
0001569329ygyi:MortgageWithLandAcquisitionInGrovelandFloridaMember2019-12-31
0001569329ygyi:LendingAgreementLoansMember2018-07-31
0001569329ygyi:LendingAgreementLoansMembersrt:MinimumMember2018-07-31
0001569329ygyi:LendingAgreementLoansMembersrt:MaximumMember2018-07-31
0001569329ygyi:M2cPurchaseAgreementMember2007-03-012007-03-31
0001569329ygyi:M2cPurchaseAgreementMember2007-03-31
0001569329ygyi:M2cPurchaseAgreementMember2020-03-31
0001569329ygyi:M2cPurchaseAgreementMember2019-12-31
0001569329ygyi:OtherNotesRelatedToLoansForCommercialVansMember2020-03-31
0001569329ygyi:OtherNotesRelatedToLoansForCommercialVansMember2019-12-31
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMember2020-03-31
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMembersrt:ScenarioForecastMember2022-01-31
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMemberus-gaap:PrimeRateMember2020-01-012020-03-31
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMember2020-01-012020-03-31
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMember2019-12-31
0001569329ygyi:PipeNotes2019Member2020-03-31
0001569329ygyi:PipeNotes2019Member2019-12-31
0001569329ygyi:PipeNotes2014Member2020-03-31
0001569329ygyi:PipeNotes2014Member2019-12-31
0001569329ygyi:The2019PrivatePlacementDebtOfferingMember2019-07-31
0001569329ygyi:The2019PrivatePlacementDebtOfferingMember2019-07-31
0001569329ygyi:SubscriptionAgreementMember2019-07-31
0001569329ygyi:PipeNotes2019Member2019-07-31
0001569329ygyi:PipeNotes2019ConvertedIntoCommonStockMember2019-07-31
0001569329ygyi:PipeNotes2019Member2020-01-012020-03-31
0001569329ygyi:PipeNotes2019AmendmentMembersrt:ScenarioForecastMember2021-03-31
0001569329ygyi:PipeNotes2014Member2014-07-012014-09-30
0001569329ygyi:PipeNotes2014Member2014-09-30
0001569329ygyi:Pipe2014DebtConvertedIntoCommonStockMember2014-07-012014-09-30
0001569329ygyi:Pipe2014DebtConvertedIntoCommonStockMember2014-09-30
0001569329ygyi:WarrantsWith2014PrivatePlacementMember2014-09-30
0001569329us-gaap:AssetNotPledgedAsCollateralMembersrt:ChiefExecutiveOfficerMember2020-03-31
0001569329ygyi:PipeNotes2014Member2019-09-30
0001569329ygyi:PipeNotes2014Member2019-01-012019-03-31
0001569329ygyi:WarrantsMember2020-03-31
0001569329ygyi:WarrantsMember2019-12-31
0001569329ygyi:WarrantsMember2020-01-012020-03-31
0001569329ygyi:WarrantsMember2019-01-012019-03-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2020-03-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2020-03-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2020-03-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2020-03-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2020-03-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2020-03-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2019-12-31
0001569329us-gaap:FairValueInputsLevel1Member2020-03-31
0001569329us-gaap:FairValueInputsLevel2Member2020-03-31
0001569329us-gaap:FairValueInputsLevel3Member2020-03-31
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel1Member2020-03-31
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel2Member2020-03-31
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel3Member2020-03-31
0001569329us-gaap:FairValueInputsLevel1Member2019-12-31
0001569329us-gaap:FairValueInputsLevel2Member2019-12-31
0001569329us-gaap:FairValueInputsLevel3Member2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel1Member2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel2Member2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel3Member2019-12-31
0001569329ygyi:WarrantsMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-03-31
0001569329us-gaap:FairValueInputsLevel3Memberygyi:ContingentLiabilitiesMember2019-12-31
0001569329us-gaap:FairValueInputsLevel3Memberygyi:ContingentLiabilitiesMember2020-01-012020-03-31
0001569329us-gaap:FairValueInputsLevel3Memberygyi:ContingentLiabilitiesMember2020-03-31
0001569329us-gaap:MeasurementInputDiscountRateMember2020-03-31
0001569329us-gaap:MeasurementInputDiscountRateMember2019-12-31
0001569329us-gaap:SeriesCPreferredStockMember2020-03-31
00015693292018-05-31
0001569329ygyi:March2020PrivatePlacementDebtOfferingMember2020-03-31
0001569329ygyi:March2020PrivatePlacementDebtOfferingMember2020-03-012020-03-31
0001569329ygyi:March2020PrivatePlacementDebtOfferingMember2020-03-31
0001569329ygyi:SeniorSecuredPromissoryNoteWithSecuritiesPurchaseAgreementMember2020-03-012020-03-31
0001569329ygyi:SeniorSecuredPromissoryNoteWithSecuritiesPurchaseAgreementMember2020-03-012020-03-31
0001569329srt:ScenarioForecastMemberygyi:SeniorSecuredPromissoryNoteWithSecuritiesPurchaseAgreementMember2021-04-012021-04-30
0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-06-012019-06-30
0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-06-30
0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-02-012019-02-28
0001569329ygyi:SecuritiesPurchaseAgreementWithDanielManglessMember2019-02-28
0001569329ygyi:WarrantsInConnectionWithSecuritiesPurchaseAgreementMember2019-02-28
0001569329ygyi:PurchaseAgreementSharesIssuedForConsultingFeesMember2019-02-012019-02-28
0001569329ygyi:PurchaseAgreementSharesIssuedForConsultingFeesMember2019-02-28
0001569329ygyi:PurchaseAgreementsWarrantsForConsultingFeesMember2019-02-28
00015693292019-03-012020-03-31
0001569329ygyi:The2019PrivatePlacementDebtOfferingMember2019-02-012019-07-31
0001569329ygyi:StockIssuedToPlacementAgentMember2019-02-012019-07-31
0001569329srt:ScenarioForecastMemberygyi:StockIssuedToPlacementAgentMember2021-02-012021-03-31
0001569329ygyi:AtthemarketEquityOfferingProgramMember2019-01-31
0001569329ygyi:AtthemarketEquityOfferingProgramMember2019-01-012019-01-31
0001569329ygyi:PrivatePlacement2018Member2018-08-012018-10-31
0001569329ygyi:PrivatePlacement2018Member2018-10-31
0001569329ygyi:StockIssuedForAdvisoryFeesMember2018-08-012018-10-31
0001569329ygyi:WarrantsInConnectionWith2018PrivatePlacementMember2018-10-31
0001569329ygyi:PrivatePlacement2018Member2019-01-012019-12-31
0001569329ygyi:WarrantsInConnectionWith2018PrivatePlacementMember2020-03-31
0001569329ygyi:WarrantsInConnectionWith2018PrivatePlacementMember2019-12-31
0001569329ygyi:WarrantsInConnectionWith2018PrivatePlacementMemberygyi:ReclassifiedFromDerivativeLiabilityToEquityMember2019-01-01
0001569329ygyi:ConversionOf2014ConvertibleNoteIntoCommonStockMember2018-10-012018-10-31
0001569329ygyi:ConversionOf2014ConvertibleNoteIntoCommonStockMember2018-10-31
0001569329ygyi:WarrantsWith2014ConvertibleNoteMember2018-10-31
0001569329ygyi:WarrantsWith2014ConvertibleNoteMember2020-03-31
0001569329ygyi:WarrantsWith2014ConvertibleNoteMember2019-12-31
0001569329ygyi:StockIssuedToDebtExchangeDealerMember2018-10-012018-10-31
0001569329ygyi:WarrantsToDebtExchangeDealerOneMember2018-10-31
0001569329ygyi:WarrantsToDebtExchangeDealerTwoMember2018-10-31
0001569329ygyi:WarrantsToDebtExchangeDealerMember2020-03-31
0001569329ygyi:WarrantsToDebtExchangeDealerMember2019-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2018-03-012018-03-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2018-03-31
0001569329ygyi:WarrantsWithSeriesBOfferingMember2018-03-012018-03-31
0001569329ygyi:WarrantsWithSeriesBOfferingMember2018-03-31
0001569329ygyi:WarrantsWithSeriesBOfferingMember2020-03-31
0001569329ygyi:WarrantsWithSeriesBOfferingMember2019-12-31
0001569329ygyi:ConversionOfSeriesBPreferredStockIntoCommonStockMember2020-01-012020-03-31
0001569329ygyi:ConversionOfSeriesBPreferredStockIntoCommonStockMember2019-01-012019-12-31
0001569329ygyi:SeriesBConvertiblePreferredStockMember2019-01-012019-03-31
0001569329ygyi:WarrantsWithSeriesCOfferingMember2018-01-012018-12-31
0001569329ygyi:WarrantsWithSeriesCOfferingMember2018-12-31
0001569329us-gaap:SeriesCPreferredStockMember2019-12-31
0001569329ygyi:WarrantsWithSeriesCOfferingMember2019-01-012019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-09-012019-12-31
0001569329srt:WeightedAverageMemberygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2019-09-012019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2019-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2020-01-012020-01-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMemberus-gaap:OverAllotmentOptionMember2020-01-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMember2019-09-012020-03-31
0001569329ygyi:CapitalMarketSolutionsLlcMember2018-07-012018-07-31
0001569329ygyi:CapitalMarketSolutionsLlcMember2020-01-012020-03-31
0001569329ygyi:CapitalMarketSolutionsLlcMember2019-01-012019-01-31
0001569329ygyi:CapitalMarketSolutionsLlcMember2019-01-31
0001569329ygyi:CapitalMarketSolutionsLlcMember2020-01-31
0001569329ygyi:CapitalMarketSolutionsLlcMembersrt:ScenarioForecastMember2021-01-31
0001569329ygyi:CapitalMarketSolutionsLlcMember2019-01-012019-03-31
0001569329ygyi:CorinthianPartnersLlcMember2019-08-012019-08-31
0001569329ygyi:GreentreeFinancialGroupIncMember2018-03-012018-03-31
0001569329ygyi:GreentreeFinancialGroupIncMember2019-01-012019-03-31
0001569329ygyi:IbankersMember2019-04-012019-04-30
0001569329ygyi:IbankersMember2020-01-012020-03-31
0001569329ygyi:IgnitionMember2018-04-012018-04-30
0001569329ygyi:IgnitionMember2019-01-012019-03-31
0001569329ygyi:IgnitionMember2019-03-012019-03-31
0001569329ygyi:IgnitionMember2019-03-31
0001569329ygyi:IvanGandrudChevroletIncMember2020-03-012020-03-31
0001569329ygyi:IvanGandrudChevroletIncMember2020-03-31
0001569329ygyi:IvanGandrudChevroletIncMember2020-01-012020-03-31
0001569329ygyi:IvanGandrudChevroletIncMemberygyi:MrDanielManglessMember2020-03-31
0001569329ygyi:BenchmarkCompanyMember2019-08-012019-08-31
0001569329srt:MinimumMember2020-03-31
0001569329srt:MaximumMember2020-03-31
0001569329us-gaap:CostOfSalesMember2020-01-012020-03-31
0001569329us-gaap:CostOfSalesMember2019-01-012019-03-31
0001569329us-gaap:SellingAndMarketingExpenseMember2020-01-012020-03-31
0001569329us-gaap:SellingAndMarketingExpenseMember2019-01-012019-03-31
0001569329us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-03-31
0001569329us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-03-31
00015693292019-01-012019-12-31
0001569329us-gaap:EmployeeStockOptionMember2020-01-012020-03-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:ConsultantsMember2019-08-012019-08-31
00015693292019-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMember2017-08-012017-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2017-08-012017-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2017-08-012017-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2017-08-012017-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMemberygyi:SharebasedPaymentArrangementTrancheFourMember2017-08-012017-08-31
00015693292017-08-31 00015693292019-01-01
0001569329us-gaap:RestrictedStockUnitsRSUMember2019-12-31
0001569329us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-31
0001569329us-gaap:RestrictedStockUnitsRSUMember2020-03-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMember2020-03-31
0001569329us-gaap:RestrictedStockUnitsRSUMemberygyi:EmployeeAndConsultantMember2020-01-012020-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:DirectSellingSegmentMember2020-01-012020-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:DirectSellingSegmentMember2020-01-012020-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:DirectSellingSegmentMember2019-01-012019-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:DirectSellingSegmentMember2019-01-012019-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:OneVendorMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialHempSegmentMember2020-01-012020-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialHempSegmentMember2020-01-012020-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:CommercialHempSegmentMember2019-01-012019-03-31
0001569329ygyi:SegmentPurchasesBenchmarkMemberus-gaap:SupplierConcentrationRiskMemberygyi:TwoVendorsMemberygyi:CommercialHempSegmentMember2019-01-012019-03-31
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-03-31
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:FourCustomersMemberygyi:CommercialCoffeeSegmentMember2020-01-012020-03-31
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-03-31
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:OneCustomerMemberygyi:CommercialCoffeeSegmentMember2019-01-012019-03-31
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialHempSegmentMember2020-01-012020-03-31
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:TwoCustomersMemberygyi:CommercialHempSegmentMember2020-01-012020-03-31
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:CommercialHempSegmentMember2019-01-012019-03-31
0001569329us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberygyi:TwoCustomersMemberygyi:CommercialHempSegmentMember2019-01-012019-03-31
0001569329ygyi:DirectSellingSegmentMember2019-03-31
0001569329ygyi:CommercialCoffeeSegmentMember2019-03-31
0001569329ygyi:CommercialHempSegmentMember2019-03-31
0001569329us-gaap:NonUsMember2020-03-31
0001569329us-gaap:NonUsMember2019-12-31
0001569329us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2020-01-012020-03-31
0001569329us-gaap:SalesRevenueNetMemberus-gaap:GeographicConcentrationRiskMemberus-gaap:NonUsMember2019-01-012019-03-31
0001569329country:US2020-01-012020-03-31
0001569329country:US2019-01-012019-03-31
0001569329us-gaap:NonUsMember2020-01-012020-03-31
0001569329us-gaap:NonUsMember2019-01-012019-03-31
0001569329us-gaap:LineOfCreditMemberygyi:CrestmarkBankMembersrt:ScenarioForecastMember2022-06-17
0001569329ygyi:MrDanielManglessMembersrt:ScenarioForecastMember2021-02-28
0001569329ygyi:AllClaimsRelatedToLawsuitFiledByMrManglessMembersrt:ScenarioForecastMember2021-04-012021-04-30
0001569329srt:ScenarioForecastMemberygyi:SettlementSharesMember2021-04-012021-04-30
0001569329ygyi:CbdOilExtractionEquipmentWithVfiMembersrt:ScenarioForecastMember2020-08-31
0001569329ygyi:CbdOilExtractionEquipmentWithVfiMembersrt:ScenarioForecastMember2020-08-012020-08-31
0001569329us-gaap:SubsequentEventMember2020-04-012020-04-30
0001569329ygyi:DirectSellingSegmentMembersrt:ScenarioForecastMember2020-04-012020-07-31
0001569329ygyi:CommercialCoffeeSegmentMembersrt:ScenarioForecastMember2020-04-012020-07-31
0001569329ygyi:CommercialHempSegmentMembersrt:ScenarioForecastMember2020-04-012020-07-31
0001569329ygyi:CommercialCoffeeSegmentMembersrt:ScenarioForecastMember2020-07-012020-07-31
0001569329ygyi:MortgageDebtMembersrt:ScenarioForecastMember2020-01-012020-12-31
0001569329srt:ScenarioForecastMember2021-02-28
0001569329ygyi:CommercialCoffeeSegmentMembersrt:ScenarioForecastMember2021-04-012021-04-30
0001569329srt:ScenarioForecastMember2021-06-012021-06-30
0001569329ygyi:DirectSellingSegmentMembersrt:ScenarioForecastMember2021-06-012021-06-30
0001569329ygyi:CommercialCoffeeSegmentMembersrt:ScenarioForecastMember2021-06-012021-06-30
0001569329ygyi:PipeNotes2019Membersrt:ScenarioForecastMember2021-02-28
0001569329srt:ScenarioForecastMemberygyi:StockInConnectionWith2019PipeNotesMember2021-02-012021-02-28
0001569329ygyi:PipeNotes2019Membersrt:ScenarioForecastMember2021-03-31
0001569329srt:ScenarioForecastMemberygyi:StockInConnectionWith2019PipeNotesMember2021-03-012021-03-31
0001569329ygyi:PromissoryNotes2019Membersrt:ScenarioForecastMember2021-02-28
0001569329srt:ScenarioForecastMemberygyi:SharesInConnectionWithPromissoryNotes2019Member2021-02-012021-02-28
0001569329ygyi:WarrantsInConnectionWithPromissoryNotes2019Membersrt:ScenarioForecastMember2021-02-28
0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2022-05-31
0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2022-05-012022-05-31
0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2021-09-30
0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2021-09-012021-09-30
0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:LendingAgreementMembersrt:MinimumMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:LendingAgreementMembersrt:MaximumMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:LendingAgreementMembersrt:ScenarioForecastMember2020-05-31
0001569329srt:ScenarioForecastMemberygyi:SharesWithHempJointVentureAgreementMember2020-07-012020-07-31
0001569329ygyi:WarrantsWithHempJointVentureAgreementMembersrt:ScenarioForecastMember2020-07-31
0001569329ygyi:NicaraguanJvPartnersMembersrt:ScenarioForecastMember2020-07-31
0001569329ygyi:UsPartnersMembersrt:ScenarioForecastMember2020-07-31
0001569329ygyi:CLRMemberygyi:HhMembersrt:ScenarioForecastMember2021-03-31
0001569329ygyi:TradeAccountsReceivablesMemberygyi:CLRMemberygyi:HhMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:CLRMemberygyi:HhMembersrt:ScenarioForecastMember2020-12-31
0001569329ygyi:GrovelandPropertyMembersrt:ScenarioForecastMember2021-05-012021-05-31
0001569329ygyi:MascotteFacilityMembersrt:ScenarioForecastMember2021-10-012021-10-31
0001569329ygyi:ClermontPropertyMembersrt:ScenarioForecastMember2022-02-012022-02-28
0001569329us-gaap:RestrictedStockUnitsRSUMembersrt:ScenarioForecastMember2020-08-012020-08-31
0001569329us-gaap:RestrictedStockUnitsRSUMembersrt:ScenarioForecastMember2021-08-012021-08-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMembersrt:ScenarioForecastMember2020-04-012020-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMembersrt:ScenarioForecastMember2021-01-012021-12-31
0001569329ygyi:SeriesDCumulativeRedeemablePerpetualPreferredStockMembersrt:ScenarioForecastMember2022-01-012022-06-15
0001569329ygyi:BeneyouMember2020-01-012020-03-31
0001569329us-gaap:ConvertibleNotesPayableMember2020-01-012020-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
|
☒
|
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For the quarterly period ended March 31, 2020
|
☐ |
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
For the transition period from ______ to ______
Commission file number: 001-38116
YOUNGEVITY
INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
|
|
90-0890517
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
2400 Boswell Road,
Chula Vista, CA
|
|
91914
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(619)
934-3980
Registrant’s Telephone Number, Including Area Code
Not
applicable
Former Name, Former Address and Former Fiscal Year, if Changed
Since Last Report
Securities registered pursuant to Section 12(b) of the Act:
None
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
N/A
|
N/A
|
N/A
|
Indicate by check mark whether the registrant (1) filed all reports
required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90
days. Yes ☐ No ☒
Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (Sec.232.405 of this
chapter) during the preceding 12 months (or for such shorter period
that the registrant was required to submit such files).
Yes ☐ No ☒
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
smaller reporting company, or an emerging growth company. See the
definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule
12b-2 of the Exchange Act.
Large accelerated filer
|
☐
|
Accelerated filer
|
☐ |
Non-accelerated filer
|
☒ |
Smaller reporting company
|
☒
|
|
|
Emerging growth company
|
☐
|
If an emerging growth company indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No ☒
At June 17, 2022, the issuer had 34,044,419 shares of its
Common Stock, par value $0.001 per share, issued and
outstanding.
YOUNGEVITY INTERNATIONAL,
INC.
TABLE OF CONTENTS
PART
I. FINANCIAL INFORMATION
Item 1. Financial Statements
Youngevity International, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
ASSETS
|
|
(Unaudited)
|
|
|
|
|
|
Current Assets
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$ |
3,243 |
|
|
$ |
4,463 |
|
Accounts receivable, net
|
|
|
2,949 |
|
|
|
2,902 |
|
Income tax receivable
|
|
|
73 |
|
|
|
81 |
|
Inventory
|
|
|
22,743 |
|
|
|
22,706 |
|
Prepaid expenses and other current assets
|
|
|
3,488 |
|
|
|
3,982 |
|
Total current assets
|
|
|
32,496 |
|
|
|
34,134 |
|
Property and equipment, net
|
|
|
23,736 |
|
|
|
23,316 |
|
Operating lease right-of-use assets
|
|
|
7,818 |
|
|
|
8,386 |
|
Deferred tax assets
|
|
|
75 |
|
|
|
75 |
|
Intangible assets, net
|
|
|
14,946 |
|
|
|
15,566 |
|
Goodwill
|
|
|
6,992 |
|
|
|
6,992 |
|
Other assets
|
|
|
1,273 |
|
|
|
1,222 |
|
Total assets
|
|
$ |
87,336 |
|
|
$ |
89,691 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
|
|
|
|
|
|
|
Current Liabilities
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$ |
10,954 |
|
|
$ |
9,069 |
|
Accrued distributor compensation
|
|
|
4,542 |
|
|
|
3,164 |
|
Accrued expenses
|
|
|
6,420 |
|
|
|
5,108 |
|
Deferred revenues, current portion
|
|
|
3,173 |
|
|
|
1,943 |
|
Other current liabilities
|
|
|
3,152 |
|
|
|
2,664 |
|
Operating lease liabilities, current portion
|
|
|
1,547 |
|
|
|
1,740 |
|
Finance lease liabilities, current portion
|
|
|
726 |
|
|
|
736 |
|
Line of credit
|
|
|
2,025 |
|
|
|
2,011 |
|
Notes payable, net of debt discounts, current portion (Note 3)
|
|
|
4,231 |
|
|
|
4,085 |
|
Notes payable, net of debt discounts, current portion
|
|
|
2,015 |
|
|
|
191 |
|
Convertible notes payable, net of debt discounts, current
portion
|
|
|
2,784 |
|
|
|
25 |
|
Contingent acquisition debt, current portion
|
|
|
1,382 |
|
|
|
1,263 |
|
Warrant derivative liability
|
|
|
53 |
|
|
|
1,542 |
|
Total current liabilities
|
|
|
43,004 |
|
|
|
33,541 |
|
Operating lease liabilities, net of current portion
|
|
|
6,473 |
|
|
|
6,646 |
|
Finance lease liabilities, net of current portion
|
|
|
258 |
|
|
|
408 |
|
Notes payable, net of current portion (Note 3)
|
|
|
1,000 |
|
|
|
- |
|
Notes payable, net of debt discounts, net of current portion
|
|
|
4,962 |
|
|
|
6,790 |
|
Convertible notes payable, net of debt discounts, net of current
portion
|
|
|
- |
|
|
|
2,675 |
|
Contingent acquisition debt, net of current portion
|
|
|
6,759 |
|
|
|
7,348 |
|
Other long-term liabilities
|
|
|
437 |
|
|
|
2,115 |
|
Total liabilities
|
|
|
62,893 |
|
|
|
59,523 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 11)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ Equity
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value:
5,000,000 shares
authorized
|
|
|
|
|
|
|
|
|
Series A – 8% convertible preferred
stock; 161,135
shares issued and outstanding at March 31, 2020 and December 31,
2019
|
|
|
– |
|
|
|
– |
|
Series B – 5% convertible preferred
stock; zero and 129,332 shares issued and
outstanding at March 31, 2020 and December 31, 2019,
respectively
|
|
|
– |
|
|
|
– |
|
Series D – 9.75% cumulative
redeemable perpetual preferred stock; 590,273 and 578,898 shares issued and
outstanding at March 31, 2020 and December 31, 2019, respectively;
$14,877 liquidation
preference at March 31, 2020
|
|
|
– |
|
|
|
– |
|
Common stock, $0.001 par value:
50,000,000 shares
authorized; 30,712,432 and
30,274,601 shares issued
and outstanding at March 31, 2020 and December 31, 2019,
respectively
|
|
|
31 |
|
|
|
30 |
|
Additional paid-in capital
|
|
|
265,867 |
|
|
|
265,825 |
|
Accumulated deficit
|
|
|
(241,542 |
)
|
|
|
(235,751 |
)
|
Accumulated other comprehensive income
|
|
|
87 |
|
|
|
64 |
|
Total stockholders’ equity
|
|
|
24,443 |
|
|
|
30,168 |
|
Total Liabilities and Stockholders’ Equity
|
|
$ |
87,336 |
|
|
$ |
89,691 |
|
See accompanying notes to condensed consolidated financial
statements.
Youngevity International, Inc. and
Subsidiaries
Unaudited Condensed Consolidated Statements of
Operations
(In thousands, except share and per share amounts)
|
|
Three Months Ended
March 31,
|
|
|
|
2020
|
|
|
2019
|
|
Revenues
|
|
$ |
35,531 |
|
|
$ |
41,192 |
|
Cost of revenues
|
|
|
15,744 |
|
|
|
14,343 |
|
Gross profit
|
|
|
19,787 |
|
|
|
26,849 |
|
Operating expenses
|
|
|
|
|
|
|
|
|
Distributor compensation
|
|
|
14,051 |
|
|
|
14,890 |
|
Sales and marketing
|
|
|
3,473 |
|
|
|
4,019 |
|
General and administrative
|
|
|
8,940 |
|
|
|
19,881 |
|
Total operating expenses
|
|
|
26,464 |
|
|
|
38,790 |
|
Operating loss
|
|
|
(6,677 |
)
|
|
|
(11,941 |
)
|
Other income (expense), net
|
|
|
|
|
|
|
|
|
Interest expense, net
|
|
|
(620 |
)
|
|
|
(1,507 |
)
|
Change in fair value of warrant derivative liability
|
|
|
1,489 |
|
|
|
1,486 |
|
Total other income (expense), net
|
|
|
869 |
|
|
|
(21 |
)
|
Net loss before income taxes
|
|
|
(5,808 |
)
|
|
|
(11,962 |
)
|
Income tax provision (benefit)
|
|
|
(17 |
)
|
|
|
298 |
|
Net loss
|
|
|
(5,791 |
)
|
|
|
(12,260 |
)
|
Preferred stock dividends
|
|
|
(379 |
)
|
|
|
(14 |
)
|
Net loss attributable to common stockholders
|
|
$ |
(6,170 |
)
|
|
$ |
(12,274 |
)
|
|
|
|
|
|
|
|
|
|
Net loss per share, basic
|
|
$ |
(0.20 |
)
|
|
$ |
(0.45 |
)
|
Net loss per share, diluted (Note 1)
|
|
$ |
(0.20 |
)
|
|
$ |
(0.49 |
)
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding, basic
|
|
|
30,314,986 |
|
|
|
27,577,576 |
|
Weighted average shares outstanding, diluted
|
|
|
30,314,986 |
|
|
|
28,025,172 |
|
See accompanying notes to condensed consolidated financial
statements.
Youngevity International, Inc. and
Subsidiaries
Unaudited Condensed Consolidated Statements of
Comprehensive Loss
(In thousands)
|
|
Three Months Ended
March 31,
|
|
|
|
2020
|
|
|
2019
|
|
Net loss
|
|
$ |
(5,791 |
)
|
|
$ |
(12,260 |
)
|
Foreign currency translation
|
|
|
23 |
|
|
|
102 |
|
Total other comprehensive income
|
|
|
23 |
|
|
|
102 |
|
Comprehensive loss
|
|
$ |
(5,768 |
)
|
|
$ |
(12,158 |
)
|
See accompanying notes to condensed consolidated financial
statements.
Youngevity International, Inc. and
Subsidiaries
Unaudited Condensed Consolidated Statements of Stockholders'
Equity
(In thousands, except shares)
|
|
Preferred Stock
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
Accumulated Other
|
|
|
|
|
|
|
|
|
|
|
|
Series A
|
|
|
Series B
|
|
|
Series D
|
|
|
Common Stock
|
|
|
Paid-in
|
|
|
Comprehensive
|
|
|
Accumulated
|
|
|
Stockholders'
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Income
|
|
|
Deficit
|
|
|
Equity
|
|
Balance at December 31, 2019
|
|
|
161,135 |
|
|
$ |
– |
|
|
|
129,332 |
|
|
$ |
– |
|
|
|
578,898 |
|
|
$ |
– |
|
|
|
30,274,601 |
|
|
$ |
30 |
|
|
$ |
265,825 |
|
|
$ |
64 |
|
|
$ |
(235,751 |
)
|
|
$ |
30,168 |
|
Net loss
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(5,791 |
)
|
|
|
(5,791 |
)
|
Foreign currency translation adjustment
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
23 |
|
|
|
– |
|
|
|
23 |
|
Issuance of common stock for conversion of Series B preferred
stock
|
|
|
– |
|
|
|
– |
|
|
|
(129,332 |
)
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
258,664 |
|
|
|
1 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
1 |
|
Issuance of common stock for vesting of RSU
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
4,167 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
Issuance of common stock for debt financing, net of issuance
costs
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
50,000 |
|
|
|
– |
|
|
|
65 |
|
|
|
– |
|
|
|
– |
|
|
|
65 |
|
Issuance of Series D preferred stock through underwritten
registered public offering, net
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
11,375 |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
233 |
|
|
|
– |
|
|
|
– |
|
|
|
233 |
|
Fair value of common stock issued related to advance for working
capital (recorded in prepaid expenses and other current assets)
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(311 |
)
|
|
|
– |
|
|
|
– |
|
|
|
(311 |
)
|
Dividends on preferred stock
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(379 |
)
|
|
|
– |
|
|
|
– |
|
|
|
(379 |
)
|
Equity-based compensation for services
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
125,000 |
|
|
|
– |
|
|
|
174 |
|
|
|
– |
|
|
|
– |
|
|
|
174 |
|
Stock-based compensation
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
260 |
|
|
|
– |
|
|
|
– |
|
|
|
260 |
|
Balance at March 31, 2020
|
|
|
161,135 |
|
|
$ |
– |
|
|
|
– |
|
|
$ |
– |
|
|
|
590,273 |
|
|
$ |
– |
|
|
|
30,712,432 |
|
|
$ |
31 |
|
|
$ |
265,867 |
|
|
$ |
87 |
|
|
$ |
(241,542 |
)
|
|
$ |
24,443 |
|
Youngevity International, Inc. and Subsidiaries
Unaudited Condensed Consolidated Statements of Stockholders'
Equity
(In thousands, except shares)
|
|
Series A Preferred Stock
|
|
|
Series B Preferred Stock
|
|
|
Common Stock
|
|
|
Additional Paid-in
|
|
|
Accumulated
Other
Comprehensive
|
|
|
Accumulated
|
|
|
Total Stockholders'
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Income (Loss)
|
|
|
Deficit
|
|
|
Equity
|
|
Balance at December 31, 2018
|
|
|
161,135 |
|
|
$ |
- |
|
|
|
129,437 |
|
|
$ |
- |
|
|
|
25,760,708 |
|
|
$ |
26 |
|
|
$ |
206,757 |
|
|
$ |
(45 |
)
|
|
$ |
(183,763 |
)
|
|
$ |
22,975 |
|
Net loss
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(12,260 |
)
|
|
|
(12,260 |
)
|
Foreign currency translation adjustment
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
102 |
|
|
|
- |
|
|
|
102 |
|
Issuance of common stock from at-the-market offering and exercise
of stock options and warrants, net
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
309,636 |
|
|
|
1 |
|
|
|
1,454 |
|
|
|
- |
|
|
|
- |
|
|
|
1,455 |
|
Issuance of common stock for services
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
75,000 |
|
|
|
- |
|
|
|
417 |
|
|
|
- |
|
|
|
- |
|
|
|
417 |
|
Issuance of common stock in private offering, net of issuance
costs
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
255,000 |
|
|
|
- |
|
|
|
1,750 |
|
|
|
- |
|
|
|
- |
|
|
|
1,750 |
|
Issuance of common stock for acquisition of Khrysos
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,794,972 |
|
|
|
1 |
|
|
|
13,999 |
|
|
|
- |
|
|
|
- |
|
|
|
14,000 |
|
Issuance of common stock for debt financing, net of issuance
costs
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
40,000 |
|
|
|
- |
|
|
|
350 |
|
|
|
- |
|
|
|
- |
|
|
|
350 |
|
Issuance of common stock for true-up shares
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
44,599 |
|
|
|
- |
|
|
|
281 |
|
|
|
- |
|
|
|
- |
|
|
|
281 |
|
Issuance of common stock for convertible note financing, net of
issuance costs
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
61,000 |
|
|
|
- |
|
|
|
293 |
|
|
|
- |
|
|
|
- |
|
|
|
293 |
|
Issuance of common stock related to purchase of land - H&H
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
153,846 |
|
|
|
- |
|
|
|
1,200 |
|
|
|
- |
|
|
|
- |
|
|
|
1,200 |
|
Issuance of common stock related to purchase of trademark -
H&H
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
100,000 |
|
|
|
- |
|
|
|
750 |
|
|
|
- |
|
|
|
- |
|
|
|
750 |
|
Issuance of common stock related to advance for working capital
(note receivable) net of settlement of debt
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
295,910 |
|
|
|
1 |
|
|
|
2,308 |
|
|
|
- |
|
|
|
- |
|
|
|
2,309 |
|
Release of warrant liability upon exercise of warrants
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
866 |
|
|
|
- |
|
|
|
- |
|
|
|
866 |
|
Release of warrant liability upon reclassification of liability to
equity
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,494 |
|
|
|
- |
|
|
|
- |
|
|
|
1,494 |
|
Warrant issued upon vesting for services
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,656 |
|
|
|
- |
|
|
|
- |
|
|
|
1,656 |
|
Dividends on preferred stock
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(14 |
)
|
|
|
- |
|
|
|
- |
|
|
|
(14 |
)
|
Stock based compensation expense
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
11,344 |
|
|
|
- |
|
|
|
- |
|
|
|
11,344 |
|
Balance at March 31, 2019
|
|
|
161,135 |
|
|
$ |
- |
|
|
|
129,437 |
|
|
$ |
- |
|
|
|
28,890,671 |
|
|
$ |
29 |
|
|
$ |
244,906 |
|
|
$ |
57 |
|
|
$ |
(196,023 |
)
|
|
$ |
48,969 |
|
Youngevity International, Inc. and
Subsidiaries
Unaudited Condensed Consolidated Statements of
Cash Flows
(In thousands)
|
|
Three Months Ended
March 31,
|
|
|
|
2020
|
|
|
2019
|
|
Cash Flows from Operating Activities:
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(5,791 |
)
|
|
$ |
(12,260 |
)
|
Adjustments to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
1,293 |
|
|
|
1,145 |
|
Stock-based compensation
|
|
|
260 |
|
|
|
11,344 |
|
Equity-based compensation for services
|
|
|
689 |
|
|
|
1,859 |
|
Amortization of debt discounts and issuance costs
|
|
|
337 |
|
|
|
199 |
|
Change in fair value of warrant derivative liability
|
|
|
(1,489 |
)
|
|
|
(1,486 |
)
|
Change in fair value of contingent acquisition debt
|
|
|
(361 |
)
|
|
|
- |
|
Decrease in allowance for accounts receivables
|
|
|
(30 |
)
|
|
|
- |
|
Change in allowance for other receivable (Note 3)
|
|
|
(311 |
)
|
|
|
- |
|
Change in allowance for notes receivable (Note 3)
|
|
|
112 |
|
|
|
- |
|
Changes in inventory reserve
|
|
|
33 |
|
|
|
159 |
|
Loss on disposal of property and equipment
|
|
|
15 |
|
|
|
- |
|
Stock issuance for true-up shares
|
|
|
- |
|
|
|
281 |
|
Noncash operating lease expense
|
|
|
568 |
|
|
|
- |
|
Changes in operating assets and liabilities, net of effect from
business combinations:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(17 |
)
|
|
|
(3,369 |
)
|
Income tax receivable
|
|
|
8 |
|
|
|
- |
|
Inventory
|
|
|
(70 |
)
|
|
|
(1,283 |
)
|
Prepaid expenses and other current assets
|
|
|
(20 |
)
|
|
|
(111 |
)
|
Other assets
|
|
|
(166 |
)
|
|
|
- |
|
Accounts payable
|
|
|
1,884 |
|
|
|
54 |
|
Accrued distributor compensation
|
|
|
1,378 |
|
|
|
854 |
|
Deferred revenues
|
|
|
1,230 |
|
|
|
(44 |
)
|
Accrued expenses and other current liabilities
|
|
|
1,812 |
|
|
|
(2,173 |
)
|
Operating lease liabilities
|
|
|
(367 |
)
|
|
|
- |
|
Other long-term liabilities
|
|
|
(1,678 |
)
|
|
|
- |
|
Net Cash Used in Operating Activities
|
|
|
(681 |
)
|
|
|
(4,831 |
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Investing Activities:
|
|
|
|
|
|
|
|
|
Acquisitions, net of cash acquired
|
|
|
- |
|
|
|
(425 |
)
|
Purchases of property and equipment
|
|
|
(1,082 |
)
|
|
|
(2,291 |
)
|
Net Cash Used in Investing Activities
|
|
|
(1,082 |
)
|
|
|
(2,716 |
)
|
|
|
|
|
|
|
|
|
|
Cash Flows from Financing Activities:
|
|
|
|
|
|
|
|
|
Proceeds from issuance of promissory notes, net of offering
costs
|
|
|
1,000 |
|
|
|
3,750 |
|
Proceeds from private placement of common stock, net of offering
costs
|
|
|
- |
|
|
|
2,267 |
|
Proceeds from at-the-market-offering and exercise of stock options
and warrants, net
|
|
|
- |
|
|
|
1,455 |
|
Proceeds from the issuance of Series D preferred stock
|
|
|
233 |
|
|
|
- |
|
Proceeds from line of credit, net
|
|
|
14 |
|
|
|
176 |
|
Payments of notes payable
|
|
|
(46 |
)
|
|
|
(35 |
)
|
Payments of contingent acquisition debt
|
|
|
(109 |
)
|
|
|
(128 |
)
|
Payments of finance leases
|
|
|
(184 |
)
|
|
|
(368 |
)
|
Payments of dividends
|
|
|
(388 |
)
|
|
|
(11 |
)
|
Net Cash Provided by Financing Activities
|
|
|
520 |
|
|
|
7,106 |
|
Foreign Currency Effect on Cash
|
|
|
23 |
|
|
|
102 |
|
Net decrease in cash and cash equivalents
|
|
|
(1,220 |
)
|
|
|
(339 |
)
|
Cash and Cash Equivalents, Beginning of Period
|
|
|
4,463 |
|
|
|
2,879 |
|
Cash and Cash Equivalents, End of Period
|
|
$ |
3,243 |
|
|
$ |
2,540 |
|
|
|
|
|
|
|
|
|
|
Supplemental Disclosures of Cash Flow Information
|
|
|
|
|
|
|
|
|
Cash paid during the period for:
|
|
|
|
|
|
|
|
|
Interest
|
|
$ |
284 |
|
|
$ |
1,034 |
|
Income taxes
|
|
$ |
- |
|
|
$ |
- |
|
|
|
|
|
|
|
|
|
|
Supplemental Disclosures of Noncash Investing and Financing
Activities
|
|
|
|
|
|
|
|
|
Purchases of property and equipment funded by mortgage
agreements
|
|
$ |
- |
|
|
$ |
450 |
|
Purchases of property and equipment funded by financing leasing
agreements
|
|
$ |
26 |
|
|
$ |
- |
|
Decrease in fair value of common stock issued for in relation to
advance for working capital (Note 3)
|
|
$ |
311 |
|
|
$ |
- |
|
Issuance of common stock for promissory note financing (Note
10)
|
|
$ |
65 |
|
|
$ |
- |
|
Fair value of stock issued for property and equipment (land)
|
|
$ |
- |
|
|
$ |
1,200 |
|
Fair value of stock issued for purchase of intangibles
(tradename)
|
|
$ |
- |
|
|
$ |
750 |
|
Fair value of stock issued for note receivable, net of debt
settlement
|
|
$ |
- |
|
|
$ |
2,309 |
|
Fair value of stock issued for services
|
|
$ |
- |
|
|
$ |
417 |
|
Fair value of stock issued in connection with the acquisition of
Khrysos Global, Inc. (Note 2)
|
|
$ |
- |
|
|
$ |
14,000 |
|
Dividends declared but not paid at the end of period (Note 10)
|
|
$ |
120 |
|
|
$ |
14 |
|
See accompanying notes to condensed
consolidated financial statements.
Youngevity International, Inc. and
Subsidiaries
Notes to Unaudited Condensed Consolidated Financial
Statements
Note 1. Description
of Business and Basis of Presentation
Description of Business
Youngevity International, Inc. (the “Company”) operates in three
segments: (i) the direct selling segment where products are offered
through a global distribution network of preferred customers and
distributors, (ii) the commercial coffee segment where products are
sold directly to businesses and (iii) the commercial hemp segment
where the Company manufactures proprietary systems to provide
end-to-end extraction and processing of hemp feed stock into hemp
oil and hemp extracts, oil extraction services, and contract
manufacturing services.
Information on the operations of the Company’s three segments is as follows:
|
●
|
The direct selling segment is operated through the Company’s
three domestic subsidiaries, AL
Global Corporation, 2400 Boswell
LLC, and Youngevity Global LLC, and twelve foreign subsidiaries:
|
|
●
|
Youngevity Australia Pty. Ltd.,
|
|
●
|
Youngevity Mexico S.A. de CV,
|
|
●
|
Youngevity Russia, LLC,
|
|
●
|
Youngevity Israel, Ltd.,
|
|
●
|
Youngevity Europe SIA (Latvia),
|
|
●
|
Youngevity Colombia S.A.S,
|
|
●
|
Youngevity International Singapore Pte. Ltd.,
|
|
●
|
Youngevity Global LLC, Taiwan Branch,
|
|
●
|
Youngevity Global LLC, Philippine Branch, and
|
|
●
|
Youngevity International (Hong Kong).
|
|
●
|
The commercial coffee business is operated through the Company’s
wholly-owned subsidiary, CLR Roasters LLC (“CLR”) and its
wholly-owned subsidiary, Siles Plantation Family Group S.A.
(“Siles”).
|
|
●
|
The commercial hemp business is operated through the Company’s
wholly-owned subsidiary, Khrysos Industries, Inc., a Delaware
corporation (“KII”). KII acquired the assets of Khrysos Global
Inc., a Florida corporation (“Khrysos Global”), in February 2019 and the wholly-owned
subsidiaries of Khrysos Global, INXL Laboratories, Inc., a Florida
corporation (“INXL”) and INX Holdings, Inc., a Florida corporation
(“INXH”).
|
In the following text, the term “the Company” refers collectively
to the Company and its subsidiaries.
Basis of Presentation
The accompanying unaudited condensed consolidated financial
statements have been prepared in accordance with the rules and
regulations of the Securities and Exchange Commission (the “SEC”)
for interim financial information. Accordingly, certain information
and footnote disclosures, normally included in financial statements
prepared in accordance with generally accepted accounting
principles, have been condensed or omitted pursuant to such rules
and regulations.
Youngevity International, Inc. (the “Company”) consolidates all
wholly-owned subsidiaries. All significant intercompany accounts
and transactions have been eliminated in consolidation.
The condensed consolidated financial statements presented at
March 31, 2020 and for the
three months ended March 31, 2020 and 2019 are unaudited. In the opinion of
management, these unaudited condensed consolidated financial
statements reflect all normal recurring and other adjustments
necessary for a fair presentation, and to make the financial
statements not misleading. These
condensed consolidated financial statements should be read in
conjunction with the audited consolidated financial statements
included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on
June 25, 2021. The results for
interim periods are not necessarily
indicative of the results for the entire year.
- 7-
Summary of Significant Accounting Policies
A summary of the Company’s significant accounting policies
consistently applied in the preparation of the accompanying
condensed consolidated financial statements follows:
Segment Information
The Company has three reportable segments: direct selling,
commercial coffee, and commercial hemp. The direct selling segment
develops and distributes health and wellness products through its
global independent direct selling network also known as multi-level
marketing. The commercial coffee segment is engaged in coffee
roasting and distribution, specializing in gourmet coffee. The
commercial hemp segment manufactures proprietary systems to provide
end-to-end extraction and processing that allow for the conversion
of hemp feed stock into hemp oil and hemp extracts. The
determination that the Company has three reportable segments is based upon the
guidance set forth in Accounting Standards Codification (“ASC”)
Topic 280, “Segment
Reporting.”
During the three months ended
March 31, 2020, the Company derived
approximately 87.7% of its revenue from its direct selling segment,
approximately 11.4% of its revenue from its commercial coffee
segment and approximately 0.9% from the commercial hemp segment.
During the three months ended
March 31, 2019, the Company derived
approximately 81.1% of its revenue from its direct selling segment,
approximately 18.7% of its revenue from its commercial coffee
segment and approximately 0.2% from the commercial hemp
segment.
Use of Estimates
The preparation of financial statements in conformity with
accounting principles generally accepted in the United States
(“GAAP”) requires the Company to make estimates and assumptions
that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenue and
expense for each reporting period. Estimates are used in
accounting for, among other things, allowances for doubtful
accounts, deferred taxes and related valuation allowances,
fair value of derivative liabilities, uncertain tax positions, loss
contingencies, fair value of options granted under the Company’s
stock and equity-based compensation plan, fair value of assets and
liabilities acquired in business combinations, finance leases,
asset impairments, estimates of future cash flows used to evaluate
impairments, useful lives of property, equipment and intangible
assets, value of contingent acquisition debt, inventory
obsolescence, and sales returns.
Actual results may differ from
previously estimated amounts and such differences may be material to the condensed consolidated
financial statements. Estimates and assumptions are reviewed
periodically, and the effects of revisions are reflected
prospectively in the period they occur.
Liquidity and Going Concern
The accompanying condensed consolidated financial statements have
been prepared and presented on a basis assuming the Company will
continue as a going concern. The Company has sustained significant
net losses during the three months
ended March 31, 2020 and 2019 of approximately $5,791,000 and
$12,260,000, respectively. Net cash used in operating activities
was approximately $681,000 and $4,831,000 for the three months ended March 31, 2020 and 2019, respectively.
Management has assessed the Company’s ability to continue as a
going concern and concluded that additional capital will be
required during the twelve-months
subsequent to the filing date of this Quarterly Report on Form
10-Q. The timing of when the
additional capital will be required is uncertain and highly
dependent on factors discussed below. There can be no assurance that the Company will be able to
execute license or purchase agreements or to obtain equity or debt
financing, or on terms acceptable to it. Factors within and outside
the Company’s control could have a significant bearing on its
ability to obtain additional financing. As a result, management has
determined that there are material uncertainties that raise
substantial doubt upon the Company’s ability to continue as a going
concern.
The Company has and continues to take actions to alleviate the cash
used in operations. During the three months ending March 31, 2020, the Company reported total
revenue of $35,531,000 a decrease of approximately 13.7% compared
to the same period a year ago. The Company continues to focus on
revenue growth, but the Company cannot make assurances that
revenues will grow. Additionally, the Company has plans to make the
necessary cost reductions and to reduce non-essential expenses,
including international operations that are not performing well to help alleviate the
cash used in operating activities.
- 8-
The outbreak of COVID-19 and
resulting pandemic resulted in significant contraction of economies
around the world and interrupted global supply chains as many
governments issued stay-at-home orders to combat COVID-19. The outbreak of COVID-19 also impacted the Company’s ability to
properly staff and maintain its domestic and international
warehousing operations due to stay-at-home orders issued within
various locations where the Company operates warehouse and shipping
operations. The Company took actions to mitigate the impact but
cannot assert that future stay-at-home orders or further
restrictive orders will not have an
impact on future operations. The Company experienced changes in
product mix demand, with demand increasing toward health-oriented
products and weakening for non-health related products. Such
changes in demand may have a
significant impact on revenues, margins and net operating profit in
the future. The outbreak also impacted the Company’s ability to
obtain some ingredients and packaging as well as ship products in
some markets. The Company’s supply chain and logistics incurred
some interruptions and cost impacts to date, and the Company could
experience more significant interruptions and cost impacts. The
Company’s suppliers of raw material and supplies have and could
continue to be impacted by geopolitical events, such as the war in
Ukraine, thus interrupting the Company’s supply chain.
Additionally, the Company’s customers may experience interruptions from other
suppliers that could cause a customer to delay or cancel orders.
These factors and other events have negatively impacted the
Company’s sales and operations and will likely continue to
negatively affect the Company’s business and financial results. The
Company is unable to predict the possible future effect on the
demand for products sold by the Company, and the related revenues,
margins and operating profit due to these events.
In addition, the outbreak of the COVID-19 coronavirus has disrupted the Company’s
operations due to absenteeism by infected or ill members of
management or other employees, or absenteeism by members of
management and other employees who elect not to come to work due to the illness
affecting others in the Company’s office or other workplace, or due
to quarantines. COVID-19 illness
could also impact members of the Company’s board of directors
resulting in absenteeism from meetings of the directors or
committees of directors and making it more difficult to convene the
quorums of the full board of directors or its committees needed to
conduct meetings for the management of the Company’s affairs.
The Company continues to seek and obtain equity or debt financing
on terms that are acceptable to the Company. Depending on market
conditions, there can be no
assurance that additional capital will be available when needed or
that, if available, it will be obtained on terms favorable to the
Company or to its stockholders.
These financial statements have been prepared on a going concern
basis, which asserts the Company has the ability in the near term
to continue to realize its assets and discharge its liabilities and
commitments in a planned manner giving consideration to the above
and expected possible outcomes. The financial statements do
not include any adjustments that
might be necessary from the outcome of this uncertainty. Within the
current operating environment due to the declared national
emergency, related to COVID 19
combined with the management plans described above the Company
cannot assert that the doubt of the Company’s ability to continue
as a going concern has been substantially alleviated, Conversely,
if the going concern assumption is not appropriate, adjustments to the carrying
amounts of the Company’s assets, liabilities, revenues, expenses
and balance sheet classifications may be necessary, and these adjustments could
be material.
- 9-
Revenue Recognition
The Company recognizes revenue from product sales when the
following five steps are completed:
i) Identify the contract with the customer; ii) Identify the
performance obligations in the contract; iii) Determine the
transaction price; iv) Allocate the transaction price to the
performance obligations in the contract; and v) Recognize revenue
when (or as) each performance obligation is satisfied.
Revenue is recognized upon transfer of control of promised products
or services to customers in an amount that reflects the
consideration the Company expects to receive in exchange for those
products or services. The Company enters into contracts that can
include various combinations of products and services, which are
generally capable of being distinct and accounted for as separate
performance obligations. Revenue is recognized net of allowances
for returns and any taxes collected from customers, which are
subsequently remitted to governmental authorities.
The transaction price for all sales is based on the price reflected
in the individual customer's contract or purchase order.
Variable consideration has not been
identified as a significant component of the transaction price for
any of the Company’s transactions.
Independent distributors receive compensation which is recognized
as distributor compensation in the Company’s consolidated
statements of operations. Due to the short-term nature of the
contract with the customers, the Company accrues all distributor
compensation expense in the month earned and pays the compensation
the following month.
The Company also charges fees to become a distributor, and earn a
position in the network genealogy, which are recognized as revenue
in the period received. The Company’s distributors are required to
pay a one-time enrollment fee and
receive a welcome kit specific to that country or region that
consists of forms, policy and procedures, selling aids, access to
the Company’s distributor website and a genealogy position with
no down line distributors.
The Company has determined that most contracts will be completed in
less than one year. For those
transactions where all performance obligations will be satisfied
within one year or less, the
Company is applying the practical expedient outlined in ASC
606-10-32-18. This
practical expedient allows the Company not to adjust promised consideration for the
effects of a significant financing component if the Company expects
at contract inception the period between when the Company transfers
the promised good or service to a customer and when the customer
pays for that good or service will be one year or less. For those transactions that
are expected to be completed after one year, the Company has assessed that there
are no significant financing
components because any difference between the promised
consideration and the cash selling price of the good or service is
for reasons other than the provision of financing.
Revenue recognition by segment is as follows:
Direct Selling. Direct distribution sales are made
through the Company’s network (direct selling segment), which is a
web-based global network of customers and distributors. The
Company’s independent sales force markets a variety of products to
an array of customers, through friend-to-friend marketing and
social networking. The Company considers itself to be an e-commerce
company whereby personal interaction is provided to customers by
its independent sales network. Sales generated from direct
distribution includes; health and wellness, beauty product and skin
care, scrap booking and story booking items, packaged food products
and other service-based products.
Revenue is recognized when the Company satisfies its performance
obligations under the contract. The Company recognizes revenue by
transferring the promised products to the customer, with revenue
recognized at shipping point, the point in time the customer
obtains control of the products. The majority of the Company’s
contracts have a single performance obligation and are short term
in nature. Sales taxes in domestic and foreign jurisdictions are
collected from customers and remitted to governmental authorities,
all at the local level, and are accounted for on a net basis and
therefore are excluded from revenues.
Commercial Coffee - Roasted Coffee. The Company
engages in the commercial sale of roasted coffee through CLR, which
is sold under a variety of private labels through major national
sales outlets and to customers including cruise lines and office
coffee service operators, and under its own Café La Rica brand,
Josie’s Java House Brand, Javalution brands and Café Cachita as
well as through its distributor network within the direct selling
segment.
Revenue is recognized when the title and risk of loss is passed to
the customer under the terms of the shipping arrangement,
typically, FOB shipping point. At this point the customer has a
present obligation to pay, takes physical possession of the
product, takes legal title to the product, bears the risks and
rewards of ownership, and as such, revenue will be recognized at
this point in time. Sales taxes in domestic and foreign
jurisdictions are collected from customers and remitted to
governmental authorities, all at the local level, and are accounted
for on a net basis and therefore are excluded from revenues.
- 10-
Commercial Coffee - Green Coffee. The commercial
coffee segment includes the sale of green coffee beans, which are
sourced from the Nicaraguan rainforest.
Revenue is recognized when the title and risk of loss is passed to
the customer under the terms of the shipping arrangement,
typically, FOB shipping point. At this point the customer has a
present obligation to pay, takes physical possession of the
product, takes legal title to the product, bears the risks and
rewards of ownership, and as such, revenue will be recognized at
this point in time. Revenues where the Company sells green coffee
beans that it has milled and where the Company has determined it is
the agent with regard to the green coffee beans is recorded at net
or recorded to reflect only the milling services provided. Sales
taxes in domestic and foreign jurisdictions are collected from
customers and remitted to governmental authorities, all at the
local level, and are accounted for on a net basis and therefore are
excluded from revenues.
Commercial Hemp. In the commercial hemp segment, the
Company develops, manufactures, and sells equipment and related
services to customers which enable them to extract CBD oils from
hemp stock. The Company provides hemp growers, feedstock suppliers,
and CBD crude oil producers the use of equipment, intellectual
capital, production consultancy, tolling services, and wholesale
CBD channel sales capabilities. The Company is also engaged in
hemp-based CBD extraction technology including tolling processing
which converts hemp crude oil to hemp extracts such as full
spectrum distillate, and cannabinoid isolate (CBD, cannabigerol or
CBG, cannabinol or CBN). The Company offers customers turnkey
manufacturing solutions in extraction services and end-to-end
processing systems. In addition, the Company provides a broad range
of capabilities in regard to formulation, quality control, and
testing standards with our CBD products, including potency analysis
for its supply partners of hemp derived CBD products. The Company
follows all guidelines for Current Good Manufacturing Practices
("CGMP") and our hemp extracts are processed, produced, and tested
throughout the manufacturing process to confirm that the
cannabinoid content meets strict company standards.
Revenue is recognized when the title and risk of loss is passed to
the customer under the terms of the shipping arrangement,
typically, FOB shipping point. At this point the customer has a
present obligation to pay, takes physical possession of the
product, takes legal title to the product, bears the risks and
rewards of ownership, and as such, revenue will be recognized at
this point in time. Sales taxes in domestic and foreign
jurisdictions are collected from customers and remitted to
governmental authorities, all at the local level, and are accounted
for on a net basis and therefore are excluded from revenues.
Contract Balances. Timing of revenue recognition
may differ from the timing of
invoicing to customers. The Company records contract assets when
performance obligations are satisfied prior to invoicing.
Contract liabilities are reflected as deferred revenues and
customer deposits in accrued expenses, deferred revenue, other
current liabilities and other long-term liabilities on the
Company’s consolidated balance sheets. Contract liabilities relate
to payments invoiced or received in advance of completion of
performance obligations and are recognized as revenue upon the
fulfillment of performance obligations. The Company recognizes
deferred revenue in its direct selling, commercial coffee and
commercial coffee segments.
In January 2020, the Company
introduced a rewards program in the direct selling segment where
its distributors earn points awards that can be redeemed for the
future product purchases. These points awards are earned by the
distributors through the purchase of products or through actions
and participation in non-product purchase activities. The Company
records the points earned through the purchase of product by
reducing revenue and creates the liability at the point of
purchase. Award points earned through non-product purchasing
activities are recorded as marketing expenses and creates the
liability at the time the distributor performs the non-revenue
activity.
The deferred revenue related to Heritage Maker’s product line
obligation for points purchased by customers represents cash
payments received that have not yet
been redeemed for product. Revenue is recognized when customers
redeem the points, and the product is shipped. Deferred revenues
related to pre-enrollment in conventions and distributor events
primarily related to the Company’s 2020 events. The Company does not recognize revenue until the conventions
or distributor events have occurred.
The Company also records deferred revenue within its direct
selling, commercial coffee and commercial hemp segments related to
payments made by customers for unshipped orders.
Deferred costs relate to Heritage Makers prepaid commissions are
recorded in prepaid expenses and other current assets on the
Company’s consolidated balance sheets and recognized in expense at
the time the related revenue is recognized.
- 11-
Plantation Costs
The Company’s commercial coffee segment includes the results of
Siles, which is comprised of (i) a 500-acre coffee plantation and
(ii) a dry-processing facility located on 26 acres, both of which
are located in Matagalpa, Nicaragua. Siles is a wholly-owned
subsidiary of CLR, and the results of CLR include the
depreciation and amortization of capitalized costs, development and
maintenance and harvesting costs of Siles. In accordance with
GAAP, plantation maintenance and harvesting costs for commercially
producing coffee farms are charged against earnings when
sold. Deferred harvest costs accumulate and are capitalized
throughout the year and are expensed over the remainder of the year
as the coffee is sold. The difference between actual harvest costs
incurred and the amount of harvest costs recognized as expense is
recorded as either an increase or decrease in deferred harvest
costs, which is reported as an asset and included with prepaid
expenses and other current assets in the condensed consolidated
balance sheets. Once the harvest is complete, the harvest costs are
then recognized as the inventory value. There were no deferred
costs associated with the harvest at March 31, 2020. Deferred costs associated
with the harvest at December 31,
2019 were approximately $350,000.
Stock-based Compensation
The Company accounts for stock-based compensation in accordance
with ASC Topic 718,
“Compensation – Stock Compensation,” which
establishes accounting for equity instruments exchanged for
services from employees and non-employees. Under such provisions,
cost is measured at the grant date, based on the calculated fair
value of the award, and is recognized as an expense net of
forfeitures, under the straight-line method, over the vesting
period of the equity grant. Forfeitures are recorded as they
occur.
The Company uses the Black-Scholes to estimate the fair value of
stock options. The use of a valuation model requires the Company to
make certain assumptions with respect to selected model inputs.
Expected volatility is calculated based on the historical
volatility of the Company’s stock price over the expected term
of the option. The expected life is based on the contractual
life of the option and expected employee exercise and post-vesting
employment termination behavior. The risk-free interest rate is
based on U.S. Treasury zero-coupon
issues with a remaining term equal to the expected life assumed at
the date of the grant.
Income Taxes
The Company accounts for income taxes in accordance with ASC
Topic 740, "Income
Taxes," under the asset and liability method which
includes the recognition of deferred tax assets and liabilities for
the expected future tax consequences of events that have been
included in the condensed consolidated financial statements. Under
this approach, deferred taxes are recorded for the future tax
consequences expected to occur when the reported amounts of assets
and liabilities are recovered or paid. The provision for income
taxes represents income taxes paid or payable for the current year
plus the change in deferred taxes during the year. Deferred taxes
result from differences between the financial statement and tax
basis of assets and liabilities and are adjusted for changes in tax
rates and tax laws when changes are enacted. The effects of future
changes in income tax laws or rates are not anticipated.
Income taxes for the interim periods are computed using the
effective tax rates estimated to be applicable for the full fiscal
year, as adjusted for any discrete taxable events that occur during
the period.
The Company files income tax returns in the U.S. on a federal basis
and in many U.S. state and foreign jurisdictions. Certain tax years
remain open to examination by the major taxing jurisdictions to
which the Company is subject.
Commitments and Contingencies
The Company is from time to time, the subject of claims and suits
arising out of matters related to the Company’s business. The
Company is party to litigation at the present time and may become party to litigation in the future.
In general, litigation claims can be expensive, and time consuming
to bring or defend against and could result in settlements or
damages that could significantly affect financial results. It is
not possible to predict the final
resolution of the current litigation to which the Company is party
to, and the impact of certain of these matters on the Company’s
business, results of operations, and financial condition could be
material. Regardless of the outcome, litigation has adversely
impacted the Company’s business because of defense costs, diversion
of management resources and other factors.
- 12-
Basic and Diluted Net Loss Per Share
Basic loss per share is computed by dividing net loss attributable
to common stockholders by the weighted-average number of common
shares outstanding during the period. Diluted loss per share is
computed by dividing net loss attributable to common stockholders
by the sum of the weighted-average number of common shares
outstanding during the period and the weighted-average number of
dilutive common share equivalents outstanding during the period,
using the treasury stock method. Dilutive common share equivalents
are comprised of stock options, restricted stock, warrants,
convertible preferred stock and common stock associated with the
Company's convertible notes based on the average stock price for
each period using the treasury stock method. Potentially dilutive
shares are excluded from the computation of diluted net loss per
share when their effect is anti-dilutive.
In periods where a net loss is presented, all potentially dilutive
securities are anti-dilutive and are excluded from the computation
of diluted net loss per share. Potentially dilutive securities for
the three months ended March 31, 2020 and 2019 were 11,895,578 and 12,882,194,
respectively.
|
|
Three Months Ended
March 31,
|
|
|
|
2020
|
|
|
2019
|
|
|
|
(unaudited) |
|
|
(unaudited) |
|
Warrants
|
|
|
6,488,182 |
|
|
|
6,943,874 |
|
Preferred stock conversions
|
|
|
20,124 |
|
|
|
275,604 |
|
Principal conversions on convertible notes
|
|
|
312,571 |
|
|
|
351,142 |
|
Stock options
|
|
|
4,631,924 |
|
|
|
4,836,574 |
|
Restricted stock units
|
|
|
442,777 |
|
|
|
475,000 |
|
Total
|
|
|
11,895,578 |
|
|
|
12,882,194 |
|
The calculation of diluted loss per share requires that, to the
extent the average market price of the underlying shares for the
reporting period exceeds the exercise price of the warrants and the
presumed exercise of such securities are dilutive to loss per share
for the period, an adjustment to net loss used in the calculation
is required to remove the change in fair value of the warrants, net
of tax from the numerator for the period. Likewise, an adjustment
to the denominator is required to reflect the related dilutive
shares, if any, under the treasury stock method. During the
three months ended March 31, 2019, the Company recorded a
valuation gain on the fair value of the warrant derivative
liability net of tax of approximately $1,409,000 which had a
dilutive impact on the loss per share.
|
|
Three Months Ended
March 31,
|
|
|
|
2020
|
|
|
2019
|
|
|
|
(unaudited) |
|
|
(unaudited) |
|
Loss per Share – Basic
|
|
|
|
|
|
|
|
|
Numerator for basic loss per share
|
|
$ |
(6,170,000 |
)
|
|
$ |
(12,274,000 |
)
|
Denominator for basic loss per share
|
|
|
30,314,986 |
|
|
|
27,577,576 |
|
Loss per common share – basic
|
|
$ |
(0.20 |
)
|
|
$ |
(0.45 |
)
|
|
|
|
|
|
|
|
|
|
Loss per Share – Diluted
|
|
|
|
|
|
|
|
|
Numerator for basic loss per share
|
|
$ |
(6,170,000 |
)
|
|
$ |
(12,274,000 |
)
|
Adjust: Fair value of dilutive warrants outstanding
|
|
|
- |
|
|
|
(1,409,000 |
)
|
Numerator for dilutive loss per share
|
|
$ |
(6,170,000 |
)
|
|
$ |
(13,683,000 |
)
|
|
|
|
|
|
|
|
|
|
Denominator for basic loss per share
|
|
|
30,314,986 |
|
|
|
27,577,576 |
|
Plus: Incremental shares underlying “in the money” warrants
outstanding
|
|
|
- |
|
|
|
447,596 |
|
Denominator for diluted loss per share
|
|
|
30,314,986 |
|
|
|
28,025,172 |
|
Loss per common share – diluted
|
|
$ |
(0.20 |
)
|
|
$ |
(0.49 |
)
|
Recently Issued and Adopted Accounting
Pronouncements
The Company does not believe that
any recently issued effective pronouncements, or pronouncements
issued but not yet effective, if
adopted, would have a material effect on the Company’s financial
statements. During the three months
ended March 31, 2020, the Company
did not adopt any accounting
pronouncements.
Note 2. Acquisitions and
Business Combinations
During 2019, the Company entered
into two acquisitions which are
detailed below. The acquisitions were conducted to allow the
Company to enter into the hemp market and expand the Company’s
distributor network within the direct selling segment, enhance and
expand its product portfolio, and diversify its product mix. As a
result of the Company’s business combinations, the Company’s
distributors and customers will have access to the acquired
company’s products and acquired company’s distributors and
customers will gain access to products offered by the
Company.
As such, the major purpose for the business combinations was to
increase revenue and profitability. The acquisitions were
structured as asset purchases which resulted in the recognition of
certain intangible assets.
During the three months ended
March 31, 2020, the Company did
not have any acquisitions.
2019 Acquisitions
BeneYOU
On October 31, 2019, the Company
entered into an asset purchase agreement with an effective date of
November 1, 2019, with BeneYOU,
LLC, a Utah limited liability company (“BeneYOU”), and Ryan
Anderson (the “BeneYOU Representing Party”), for the Company to
acquire certain assets of BeneYOU to including all of the
outstanding equity of BeneYOU Holding, LLC, a Utah limited
liability company (“BeneYOU Holding”), collectively “BeneYOU”. In
accordance with the asset purchase agreement, the Company also
acquired BeneYOU’s customer and distributor organization lists, all
intellectual property, product formulations, products, product
packaging, product registrations, licenses, marketing materials,
sales tools and swag, and all saleable inventory. BeneYOU’s
flagship brand Jamberry has an extensive line of nail products with
a core competency in social selling, and two other brands including Avisae which
focuses on the gut health and the M.Global brand of products that
includes hydration products.
The Company is obligated to make monthly payments based on a
percentage of the BeneYOU distributor revenue derived from sales of
the Company’s products and a percentage of royalty revenue derived
from sales of BeneYOU products until the earlier of the date that
is ten years from the closing date
or such time as the Company has paid to BeneYOU aggregate cash
payments of the BeneYOU distributor revenue and royalty revenue
equal to the maximum aggregate purchase price of $3,500,000. In
addition, the Company paid an acquisition liability payment of
$200,000 on the closing date, which reduced the maximum aggregate
purchase price to $3,300,000.
The contingent consideration’s estimated fair value at the date of
acquisition was approximately $2,648,000 as determined by
management using a discounted cash flow methodology. The
acquisition related costs, such as legal costs and other
professional fees were minimal and expensed as incurred.
The purchase agreement contains customary representations,
warranties and covenants of the Company, BeneYOU and the BeneYOU
Representing Party. Subject to certain customary limitations the
BeneYOU Representing Party have agreed to indemnify the Company and
BeneYOU against certain losses related to, among other things,
breaches of the BeneYOU Representing Party’s representations and
warranties, certain specified liabilities and the failure to
perform covenants or obligations under the purchase agreement.
The Company recorded the fair value at the date of acquisition of
the acquired tangible and intangible assets and liabilities as
follows (in thousands):
Contingent consideration
|
|
$ |
2,648 |
|
Aggregate purchase price
|
|
$ |
2,648 |
|
The following table summarizes the fair values of the assets
acquired and liabilities assumed in November 2019 (in thousands):
Current assets (excluding inventory)
|
|
$ |
408 |
|
Inventory (net of $469 reserve)
|
|
|
441 |
|
Trademarks and trade name
|
|
|
343 |
|
Distributor organization
|
|
|
1,175 |
|
Customer relationships
|
|
|
44 |
|
Non-compete agreement
|
|
|
277 |
|
Goodwill
|
|
|
669 |
|
Current liabilities
|
|
|
(709 |
)
|
Net assets acquired
|
|
$ |
2,648 |
|
The reported fair value of intangible assets acquired of $1,839,000
was determined through the use of a third-party valuation firm using various
income and cost approach methodologies. Specifically, the
intangibles identified in the acquisition were trademarks and trade
name, distributor organization, customer relationships and
non-compete agreement and are being amortized over their estimated
useful life of 5 years, 9 years, 5 years and 4 years, respectively.
The straight-line method is being used and is believed to
approximate the timeline within which the economic benefit of the
underlying intangible asset will be realized.
Goodwill of $669,000 was recognized as the excess purchase price
over the acquisition-date fair value of net assets acquired.
Goodwill is estimated to represent the synergistic values expected
to be realized from the combination of the two businesses. The goodwill is expected to
be deductible for tax purposes.
The pro-forma effect assuming the business combination with BeneYOU
discussed above had occurred at the beginning of 2019 is not
presented as the information was not available.
- 14-
Khrysos Global, Inc.
On February 12, 2019, the Company
and KII entered into an asset and equity purchase agreement (the
“AEPA”) with Khrysos Global, and Leigh Dundore and Dwayne Dundore
(collectively, the “Khrysos Representing Party”), for KII to
acquire substantially all the assets of Khrysos Global and all the
outstanding equity of INXL and INXH. The collective business
manufactures proprietary systems to provide end-to-end extraction
and processing that allow for the conversion of hemp feed stock
into hemp oil and hemp extracts.
The aggregate consideration payable for the assets of Khrysos
Global and the equity of INXL and INXH of $16,000,000 is to be paid
as set forth under the terms of the AEPA and allocated between
Khrysos Global and Leigh Dundore in such manner as they determine
at their discretion.
At closing on February 15, 2019,
Khrysos Global and the Khrysos Representing Party received an
aggregate of 1,794,972 shares of the Company’s common stock which
had a value of $14,000,000 for the purposes of the AEPA and
$500,000 in cash. The fair value of the common stock calculated as
part of the acquisition valuation was approximately $14,000,000. In
addition, the Company agreed to pay the sellers $1,500,000 in cash
towards the AEPA of which $1,000,000 was paid to Khrysos Global and
the Khrysos Representing Party during 2019. The remaining cash payment of $500,000
was not paid at the filing date
herewith as the Company continues to evaluate the terms of the
acquisition agreement in conjunction with the termination of the
KII President, noted below. At March 31,
2020 and December 31, 2019,
the Company’s remaining liability of $500,000 was outstanding and
recorded as accrued expenses on the condensed consolidated balance
sheet.
The AEPA contains customary representations, warranties and
covenants of the Company, Khrysos Global and the Khrysos
Representing Party. Subject to certain customary limitations
Khrysos Global and the Khrysos Representing Party have agreed to
indemnify the Company and KII against certain losses related to,
among other things, breaches of the Khrysos Representing Party’s
representations and warranties, certain specified liabilities and
the failure to perform covenants or obligations under the AEPA.
In conjunction with the acquisition and organization of KII, the
Company retained Dwayne Dundore as President of KII. Previously
agreed-upon equity compensation in the form of warrants that was to
be provided as part of the closing to Dwayne Dundore by the Company
were mutually terminated. Effective September 17, 2020, Dwayne Dundore was
no longer employed with KII or the
Company.
The Company has estimated fair value at the date of acquisition of
the acquired tangible and intangible assets and liabilities as
follows (in thousands):
Present value of cash consideration
|
|
$ |
1,894 |
|
Estimated fair value of common stock issued
|
|
|
14,000 |
|
Aggregate purchase price
|
|
$ |
15,894 |
|
The following table summarizes the estimated and as adjusted fair
values of the assets acquired and liabilities assumed in February 2019 (in thousands):
Current assets
|
|
$ |
636 |
|
Inventory
|
|
|
1,264 |
|
Property, plant and equipment
|
|
|
1,133 |
|
Trademarks and trade name
|
|
|
1,876 |
|
Customer-related intangible
|
|
|
5,629 |
|
Non-compete intangible
|
|
|
956 |
|
Goodwill
|
|
|
6,831 |
|
Current liabilities
|
|
|
(1,904 |
)
|
Notes payable
|
|
|
(527 |
)
|
Net assets acquired
|
|
$ |
15,894 |
|
The reported fair value of intangible assets acquired in the amount
of $8,461,000 was determined through the use of a third-party valuation firm using various
income and cost approach methodologies. Specifically, the
intangibles identified in the acquisition were trademarks and trade
name, customer relationships and non-compete agreement. The
trademarks and trade name, customer relationships and
non-compete agreement are being amortized over their estimated
useful life of 8 years, 4 years and 6 years, respectively. The
straight-line method is being used and is believed to approximate
the timeline within which the economic benefit of the underlying
intangible asset will be realized. In connection with the Company’s
annual impairment test in 2019, the
net book value of intangible assets of $8,461000 was determined to
be impaired. (See Note 5)
Goodwill of $6,831,000 was recognized as the excess purchase price
over the acquisition-date fair value of net assets acquired. In
connection with the Company’s annual impairment test in 2019, the full amount of goodwill recognized
was determined to be impaired.
The costs related to the acquisition are included in legal and
accounting fees and were expensed as incurred.
The pro-forma effect assuming the business combination with KII
discussed above had occurred at the beginning of 2019 is not
presented as the information was not available.
Note 3. Related
Party Transactions
Hernandez, Hernandez, Export Y Company and H&H Coffee
Group Export Corp.
The Company’s wholly-owned subsidiary, CLR, is associated with
Hernandez, Hernandez, Export Y Company (“H&H”), a Nicaragua
company, through sourcing arrangements to procure Nicaraguan grown
green coffee beans. As part of the 2014 Siles acquisition, CLR engaged the
owners of H&H, Alain Piedra Hernandez (“Mr. Hernandez”) and
Marisol Del Carmen Siles Orozco (“Ms. Orozco”), as employees to
manage Siles.
- 15-
H&H is a sourcing agent that purchases raw green coffee beans
from the local producers in Nicaragua and supplies CLR’s mill with
unprocessed green coffee for processing. CLR does not have a direct relationship with the local
producers and is dependent on H&H to negotiate agreements with
local producers for the supply and provide to CLR’s mill raw
unprocessed green coffee to CLR in a timely and efficient manner.
During the three months ended
March 31, 2019, CLR’s largest
customer for green coffee beans was H&H Coffee Group Export
Corp. (“H&H Export”), a company related to H&H. In
consideration for H&H's sourcing of green coffee for processing
within CLR’s mill, CLR and H&H share in the green coffee profit
from milling operations.
During the three months ended
March 31, 2020, CLR had purchases
from H&H and H&H Export of approximately $991,000 and
$271,000, respectively. CLR made purchases of green coffee from
H&H of approximately $2,576,000 during the three months ended March 31, 2019.
During the three months ended
March 31, 2020 and 2019, CLR recorded net revenues from green
coffee milling and processing services of approximately $168,000
and $4,826,000 respectively, from H&H Export.
At March 31, 2020 and December 31, 2019, CLR's accounts receivable
balances for customer related revenue from H&H Export was
$8,707,000, of which the full amounts were past due at the
respective periods. As a result, the Company reserved $7,871,000 as
bad debt related to the accounts receivable balances for both
periods, which was net of collections through December 31, 2020.
At March 31, 2020, the following
balances were recorded from transactions with H&H:
|
●
|
Prepaid expenses and other current assets of approximately $640,000
related to green coffee acquisition,
|
|
●
|
accounts payable of $230,000 related to billings for freight and
other charges by H&H,
|
|
●
|
accrued expenses of $60,000 primarily related to mill operation
costs, and
|
|
●
|
accrued expenses offset of $88,000 related to overpaid cost of
green coffee.
|
H&H Finance Agreement
In March 2020, CLR entered into a
Finance, Security and ARAP Monetization Agreement (the “H&H
Finance Agreement”) with H&H Export Y CIA. LTDA and
H&H Export (collectively, the “H&H Export Group”). The
H&H Finance Agreement was designed to provide the Company with
access to a continued supply of unprocessed green coffee beans for
the 2020 growing season and a
solution for funding of the continued operations of the Company’s
green coffee distribution business. Pursuant to the Agreement, the
H&H Export Group had agreed to allow a Nicaraguan agency (the
“Nicaraguan Agency”) to advance on behalf of the H&H Export
Group, approximately $22,000,000 of the $30,100,000 of accounts
receivable owed by H&H Export to CLR for its purchase of
processed green coffee during the 2019 season. The Nicaraguan Agency also
entered into a $46,500,000 credit facility with the H&H Export
Group to provide funding for the H&H Export Group’s future
coffee purchases of unprocessed green coffee from independent
producers. Of the 2020 sales
amounts to be billed by CLR for future coffee purchases of
processed coffee, CLR was to be paid an additional amount, at a
rate of $0.225 per pound of processed green coffee shipped to
customers, to be applied to the remaining outstanding 2019 accounts receivable balance owed by
H&H Export to CLR. Until such time as the entire accounts
receivable balance is paid in full, H&H Export has agreed
not take any profit interest.
However, given the COVID crisis’ impact on the 2020 growing season and the continued delay
in full payment of the 2020
receivable balances, management considered H&H Export accounts
receivable impaired at March 31,
2020. Subsequent to the H&H Finance Agreement, CLR adopted
the recognition of recording revenues at net for sales between CLR
and H&H Export.
In March 2021, CLR entered into a
master relationship agreement with the owners of H&H in order
to memorialize the various agreements and modifications to those
agreements. (See Note 13)
H&H Export Note Receivable
In December 2018, CLR advanced
$5,000,000 to H&H Export to provide services in support of a
five-year contract for the sale and
processing of 41 million pounds of
green coffee beans on an annual basis. The services include
providing hedging and financing opportunities to producers and
delivering harvested coffee to the Company’s mills. In
March 2019, this advance was
converted to a $5,000,000 loan agreement as a note receivable and
bears interest at 9.00% per annum and is due and payable by H&H
Export at the end of each year’s harvest season, but no later than October 31 for any harvest year. In
October 2019, CLR and H&H
Export amended the March 2019
agreement in terms of the maturity date such that all outstanding
principal and interest was due and payable at the end of the
2020 harvest (or when the
2020 season’s harvest was exported
and collected), but never to be later than November 30, 2020.
Management reviewed the security against the loan and the impact of
the underlying COVID crisis and determined that the full amount of
the note receivable including interest of approximately $5,452,000
and $5,340,000 was not collected at
March 31, 2020 and December 31, 2019, respectively, and
therefore the full amounts were recognized as an allowance for
collectability at the end of each respective period.
- 16-
Mill Construction Agreement between CLR and
H&H
In January 2019, to accommodate
CLR’s green coffee purchase contract, CLR entered into a mill
construction agreement with H&H and H&H Export, Mr.
Hernandez and Ms. Orozco (together with H&H, collectively
referred to as the “Nicaraguan Partner”), pursuant to which the
Nicaraguan Partner agreed to transfer a 45-acre tract of land in
Matagalpa, Nicaragua (the “Matagalpa Property”) to be owned 50% by
the Nicaraguan Partner and 50% by CLR. In consideration for the
land acquisition the Company issued to H&H Export, 153,846
shares of common stock. The fair value of the shares issued was
$1,200,000 and was based on the stock price on the date of issuance
of the shares. In addition, the Nicaraguan Partner and CLR agreed
to contribute $4,700,000 each toward construction of a processing
plant, office, and storage facilities on the Matagalpa Property
(collectively the “Matagalpa Mill”) for processing coffee in
Nicaragua. The addition of the mill will accommodate CLR’s green
coffee contract commitments.
For the three months ended
March 31, 2020 and 2019, CLR made payments of approximately
$300,000 and $1,350,000, respectively, towards the construction of
the Matagalpa Mill project.
At March 31, 2020, CLR contributed
a total of $3,350,000 towards the construction of the Matagalpa
Mill project, which is included in construction in process within
property and equipment, net on the Company's consolidated balance
sheets, and paid a total of $391,000 for operating equipment. At
March 31, 2020, the Nicaraguan
Partner contributed a total of $2,513,000 towards the Matagalpa
Mill project. At the filing date of this Quarterly Report on Form
10-Q, the Matagalpa Mill was still
incomplete for total operations.
In January 2019, the Company issued
295,910 shares of common stock to H&H Export to pay for certain
working capital, construction and other payables. In connection
with the issuance, the Company over issued 121,649 shares of common
stock, resulting in the net issuance of common stock to settle
payables of 174,261 shares. H&H Export agreed to reimburse CLR
for the over issuance of the 121,649 shares of common stock in
cash. At March 31, 2020 and
December 31, 2019, the value of the
shares was approximately $85,000 and $397,000, respectively, based
on the stock price at the respective periods. Management reviewed
the amount due in conjunction with the impact of the underlying
COVID crisis and has determined that the full receivable balances
were more than likely to be uncollected at March 31, 2020 and December 31, 2019, and therefore the full
amount was recognized as an allowance for collectability at the
respective periods.
Amended Operating and Profit-Sharing Agreement between CLR
and H&H
In January 2019, CLR entered into
an amendment to the March 2014
operating and profit-sharing agreement with the owners of H&H.
In addition, CLR and H&H, Mr. Hernandez and Ms. Orozco
restructured their profit-sharing agreement in regard to profits
from green coffee sales and processing that increased CLR’s profit
participation by an additional 25%. Under the new terms of the
agreement with respect to profit generated from green coffee sales
and processed from La Pita or the Matagalpa Mill, now will provide
for a split of profits of 75% to CLR and 25% to the Nicaraguan
Partner, after certain conditions are met. Profit-sharing
income for the three months ended
March 31, 2020 was approximately
$115,000 and profit-sharing expense for the three months ended March 31, 2019 was $243,000, which was
included in accrued expenses on the Company’s balance
sheets.
Other Agreements between CLR, H&H and H&H
Export
In January 2019, H&H Export
sold to CLR its espresso brand Café Cachita in consideration of the
issuance of 100,000 shares of the Company’s common stock. The
shares of common stock issued were valued at $7.50 per share.
In May 2017, CLR entered a
settlement agreement, as amended, with Mr. Hernandez who was issued
a warrant for the purchase of 75,000 shares of the Company’s common
stock at a price of $2.00 with an expiration date of three years, in lieu of an
obligation due from CLR to H&H as relates to a sourcing and
supply agreement with H&H and H&H Export. The warrants were
outstanding at both March 31, 2020
and December 31, 2019 and expired
in May 2020.
Other Related Party Transactions
Richard Renton
Richard Renton was a member of the board of directors until
February 11, 2020 and owns and
operates WVNP, Inc., a supplier of certain inventory items sold by
the Company. The Company made purchases from WVNP Inc. of
approximately $56,000 and $8,000 for the three months ended March 31, 2020 and 2019, respectively. In addition, Mr. Renton
is a distributor of the Company and was paid distributor
commissions of $81,000 and $94,000 for the three months ended March 31, 2020 and 2019, respectively.
- 17-
Carl Grover (Estate of Carl Wilford
Grover)
Carl Grover was the sole beneficial owner of in excess of
5% of the Company’s outstanding
common shares at March 31, 2020 and
December 31, 2019.
At March 31, 2020 and December 31, 2019, the balance of the
borrowing, net of debt discounts, from the credit agreement the
Company entered into with Mr. Grover in December 2018 was approximately $4,294,000
and $4,085,000, respectively. (See Note 6)
In July 2019, Mr. Grover acquired
600,242 shares of the Company's common stock upon the partial
exercise at $4.60 per share of a 2014 warrant to purchase 782,608 shares of
common stock held by him. In connection with such exercise, the
Company received approximately $2,761,000 from Mr. Grover, issued
to Mr. Grover 50,000 shares of restricted common stock as an
inducement fee and agreed to extend the expiration date of the
July 2014 warrant held by him to
December 15, 2020, and the exercise
price of the warrant was adjusted to $4.75 with respect to 182,366
shares of common stock remaining for exercise thereunder.
Paul Sallwasser
Mr. Paul Sallwasser is a member of the board directors, and prior
to joining the Company’s board of directors he acquired in the
Company’s 2014 private placement a
note in the principal amount of $75,000 convertible into 10,714
shares of common stock and a warrant exercisable for 14,673 shares
of common stock. Mr. Sallwasser additionally acquired in the
Company’s 2017 private placement a
note in the principal amount of $38,000 convertible into 8,177
shares of common stock and a warrant issued to purchase 5,719
shares of common stock. Mr. Sallwasser also acquired, as part of
the 2017 private placement in
exchange for the 2015 note that he
acquired in the Company’s 2015
private placement, an additional 2017 note in the principal amount of $5,000
convertible into 1,087 shares of common stock and a 2017 warrant exercisable for 543 shares of
common stock.
In March 2018, the Company
completed its Series B offering and in accordance with the terms of
the 2017 notes, Mr. Sallwasser’s
2017 notes converted to 9,264
shares of the Company’s common stock. Mr. Sallwasser’s 2017 warrants of to purchase an aggregate
6,262 shares of common stock expire between July and August during 2020.
In August 2019, Mr. Sallwasser
acquired 14,673 shares of the Company's common stock upon the
exercise of his 2014 warrant. In
connection with the exercise, Mr. Sallwasser applied approximately
$67,000 of the proceeds of his 2014
note due to him from the Company as consideration for the warrant
exercise. The warrant exercise proceeds to the Company would have
been approximately $67,000. The Company paid the balance owed to
him under his 2014 note including
accrued interest of approximately $8,000.
At March 31, 2020 and 2019, Mr. Sallwasser owned 76,924 shares of
common stock and options to purchase an aggregate of 116,655 shares
of common stock, which are exercisable.
Daniel Mangless
Daniel Mangless became a beneficial owner of in excess of
5% of the Company’s outstanding
common stock upon consummation of a securities purchase agreement
transaction in March 2020.
In February 2019, the Company
entered into a securities purchase agreement with Mr. Mangless
pursuant to which the Company sold 250,000 shares of common stock
at an offering price of $7.00 per share. Pursuant to the purchase
agreement, the Company also issued Mr. Mangless a three-year warrant to purchase
250,000 shares of common stock at an exercise price of $7.00. The
Company received proceeds of $1,750,000 from the stock offering.
(See Note 10)
In June 2019, the Company entered
into a second securities purchase
agreement with Mr. Mangless pursuant to which the Company sold
250,000 shares of common stock at an offering price of $5.50 per
share. The Company received proceeds of $1,375,000 from the stock
offering. (See Note 10)
In March 2020, the Company entered
into a securities purchase agreement with Mr. Mangless, pursuant to
which the Company issued a senior secured promissory note in the
principal amount of $1,000,000 which matured in December 2020. In addition, the Company
issued 50,000 shares of common stock in connection with this senior
secured promissory note. (See Note 6 and 10)
In April 2021, the Company entered
into a settlement agreement with Mr. Mangless related to the
payment schedule of the senior secured promissory note issued in
March 2020. In addition, as part of
the settlement agreement the Company issued Mr. Mangless 1,000,000
shares of common stock. (See Note 13)
In February 2021, Mr. Mangless
liquated some of his Youngevity common stock and is no longer a beneficial owner of in excess of
5% of the outstanding shares of
common stock. (See Note 13)
- 18-
2400 Boswell LLC
2400 Boswell, LLC (“2400 Boswell”) is the owner and lessor of
the building occupied by the Company for its corporate office and
warehouse in Chula Vista, California. The Company acquired
2400 Boswell from an immediate
member of the Company’s Chief Executive Officer in 2013. (See Note 6)
JJL Equipment Holding, LLC
In connection with the acquisition of Khrysos Global, the Company
held a deposit from JJL Equipment Holding, LLC (“JJL Equipment”)
for an equipment purchase of approximately $230,000 and $233,000 on
March 31, 2020 and December 31, 2019, respectively. Leigh
Dundore is a member and part owner of JJL Equipment. The deposit is
to be applied to future machinery and equipment orders from JJL
Equipment and was recorded in other current liabilities in the
consolidated balance sheet.
Youngevity Be the Change Foundation
Youngevity Be the Change Foundation (the “Youngevity Foundation”)
was formed in 2013 as a 501 c 3
charitable organization. The Company’s Chief Executive Officer and
its President and Chief Investment Officer both serve as officers
and directors of the Youngevity Foundation, as well as the
Company’s Chief Operating Officer and the wife of the Chief
Investment Officer who both serve as a director of the Youngevity
Foundation. During the three months
ended March 31, 2020 and 2019, the Company recorded a liability for
future contributions of $24,000 and $20,000, respectively, to the
Youngevity Foundation. At March 31,
2020 and December 31, 2019,
the liability representing future contributions to be made to the
Youngevity Foundation by the Company was $381,000 and $357,000,
respectively, and was included in current liabilities on the
Company’s consolidated balance sheets. The Company did not make any contribution
during the three months ended
March 31, 2020 and 2019.
Daniel Briskie and Maida Briskie
Daniel Briskie and Maida Briskie, the father and mother of the
Company’s Chief Investment Officer, entered into note purchase
agreements in the principal amount of $25,000 in September 2014 related to the Company’s
private placement offering in 2014. In September 2019, the Company entered into an
agreement with Daniel Briskie and Maida Briskie to extend the
maturity date of their 2014 PIPE
Note for one year. At March 31, 2020 and December 31, 2019, the balance of the loan
was $25,000. (See Note 7).
Douglas Briskie
Douglas Briskie, the brother of the Company’s Chief Investment
Officer, entered into note purchase agreements in the principal
amount of $50,000 in August 2014
related to the Company’s private placement offering in 2014. The note was paid in full in
August 2019. (See Note 7).
Note 4. Revenues
The following table summarizes disaggregated revenue by segment (in
thousands):
|
|
Three Months Ended
March 31,
|
|
|
|
2020
|
|
|
2019
|
|
|
|
(unaudited) |
|
|
(unaudited) |
|
Direct selling
|
|
$ |
31,156 |
|
|
$ |
33,420 |
|
Commercial coffee:
|
|
|
|
|
|
|
|
|
Processed green coffee
|
|
|
519 |
|
|
|
100 |
|
Milling and processing services
|
|
|
168 |
|
|
|
4,826 |
|
Roasted coffee and other
|
|
|
3,372 |
|
|
|
2,779 |
|
Total commercial coffee
|
|
|
4,059 |
|
|
|
7,705 |
|
Commercial hemp
|
|
|
316 |
|
|
|
67 |
|
Total
|
|
$ |
35,531 |
|
|
$ |
41,192 |
|
Contract Balances
On March 31, 2020 and December 31, 2019, deferred revenues were
approximately $5,535,000 and $3,569,000, respectively. Deferred
revenues in the direct selling segment related to customer deposits
were $1,925,000 and $1,626,000 on March
31, 2020 and December 31,
2019, respectively. Deferred revenues in the direct selling
segment related to the rewards program that began at the beginning
of 2020 were $1,146,000 on
March 31, 2020. Deferred revenues
in the direct selling segment related to Heritage Makers were
$1,688,000 and $1,795,000 on March 31,
2020 and December 31, 2019,
respectively. Deferred revenues related to convention and
distributor events were $158,000 and $148,000 on March 31, 2020 and December 31, 2019, respectively.
Deferred revenues in the commercial coffee segment related to
customer deposits were $618,000 on March
31, 2020. The commercial coffee segment did not have a deferred revenue
balance at December 31, 2019.
The commercial hemp segment did not have a deferred
revenue balance at March 31, 2020
or December 31, 2019.
The following table summarizes the classification of deferred
revenues balances on the balance sheets (in thousands):
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited)
|
|
|
|
|
|
Deferred revenue
|
|
$ |
3,173 |
|
|
$ |
1,943 |
|
Other current liabilities
|
|
|
1,925 |
|
|
|
1,626 |
|
Deferred revenue, current portion
|
|
|
5,098 |
|
|
|
3,569 |
|
Other long-term liabilities
|
|
|
437 |
|
|
|
- |
|
Deferred revenue, total
|
|
$ |
5,535 |
|
|
$ |
3,569 |
|
Of the deferred revenue balance on December 31, 2019, the Company recognized
revenue of approximately $369,000 from the Heritage Makers product
line and the remaining balance from the Company’s convention and
distributor events during the three
months ended March 31, 2020.
At March 31, 2020 and December 31, 2019, the balance in deferred
costs related to prepaid commissions from Heritage Makers was
approximately $227,000 and $254,000, respectively.
- 19-
Note 5. Selected Consolidated
Balance Sheet Information
Accounts Receivable, net
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited) |
|
|
|
|
Accounts receivable
|
|
$ |
11,159 |
|
|
$ |
11,142 |
|
Allowance for doubtful accounts
|
|
|
(8,210 |
)
|
|
|
(8,240 |
)
|
Accounts receivable, net
|
|
$ |
2,949 |
|
|
$ |
2,902 |
|
On March 31, 2020 and December 31, 2019, CLR's accounts receivable
balance for customer related revenue by H&H Export was
approximately $8,707,000, of which the full amounts were past due
at the respective periods. As a result, the Company reserved
$7,871,000 as bad debt related to the accounts receivable balances
for both periods, which was net of collections through December 31, 2020.
Inventory, net
Inventories consist of the following (in thousands):
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited) |
|
|
|
|
Finished goods
|
|
$ |
13,499 |
|
|
$ |
14,890 |
|
Raw materials
|
|
|
13,155 |
|
|
|
11,694 |
|
Total inventory
|
|
|
26,654 |
|
|
|
26,584 |
|
Reserve for excess and obsolete
|
|
|
(3,911 |
)
|
|
|
(3,878 |
)
|
Inventory, net
|
|
$ |
22,743 |
|
|
$ |
22,706 |
|
Property and Equipment, net
Property and equipment consist of the following (in thousands):
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited) |
|
|
|
|
Buildings
|
|
$ |
4,346 |
|
|
$ |
4,789 |
|
Leasehold improvements
|
|
|
3,054 |
|
|
|
2,948 |
|
Land
|
|
|
2,254 |
|
|
|
3,307 |
|
Land improvements
|
|
|
606 |
|
|
|
606 |
|
Producing coffee trees
|
|
|
553 |
|
|
|
553 |
|
Manufacturing equipment
|
|
|
10,069 |
|
|
|
9,568 |
|
Furniture and other equipment
|
|
|
2,191 |
|
|
|
2,050 |
|
Computer software
|
|
|
1,442 |
|
|
|
1,420 |
|
Computer equipment
|
|
|
2,651 |
|
|
|
2,648 |
|
Vehicles
|
|
|
362 |
|
|
|
326 |
|
Assets held for sale (1)
|
|
|
1,496 |
|
|
|
- |
|
Construction in process
|
|
|
6,843 |
|
|
|
6,562 |
|
Total property and equipment, gross
|
|
|
35,867 |
|
|
|
34,777 |
|
Accumulated depreciation
|
|
|
(12,131 |
)
|
|
|
(11,461 |
)
|
Total property and equipment, net
|
|
$ |
23,736 |
|
|
$ |
23,316 |
|
(1)
|
Assets held for sale at March 31,
2020 consisted of approximately $1,053,000 in land and
$443,000 in building related to the commercial hemp segment. (See
Note 13)
|
Depreciation expense totaled approximately $673,000 and $475,000
for the three months ended
March 31, 2020 and 2019, respectively.
- 20-
Operating and Financing Leases
The Company’s operating and financing lease assets and liabilities
recognized within its consolidated balance sheets were classified
as follows (in thousands):
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited)
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Operating lease right-of-use assets
|
|
$ |
7,818 |
|
|
$ |
8,386 |
|
Finance lease right-of-use assets (1)
|
|
|
907 |
|
|
|
1,052 |
|
Total leased assets
|
|
$ |
8,725 |
|
|
$ |
9,438 |
|
Liabilities
|
|
|
|
|
|
|
|
|
Operating lease liabilities, current portion
|
|
$ |
1,547 |
|
|
$ |
1,740 |
|
Finance lease liabilities, current portion
|
|
|
726 |
|
|
|
736 |
|
Total leased liabilities, current portion
|
|
|
2,273 |
|
|
|
2,476 |
|
Operating lease liabilities, net of current portion
|
|
|
6,473 |
|
|
|
6,646 |
|
Finance lease liabilities, net of current portion
|
|
|
258 |
|
|
|
408 |
|
Total lease liabilities
|
|
$ |
9,004 |
|
|
$ |
9,530 |
|
(1)
|
Finance lease right-of-use assets are recorded within property and
equipment, net of accumulated amortization of approximately
$1,548,000 and $1,367,000 at March 31,
2020 and December 31, 2019,
respectively.
|
The weighted-average remaining lease term and weighted-average
discount rate used to calculate the present value of lease
liabilities are as follows:
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited)
|
|
|
|
|
|
Weighted-average remaining lease term (in years)
|
|
|
|
|
|
|
|
|
Operating leases
|
|
|
6.7 |
|
|
|
6.8 |
|
Finance leases
|
|
|
1.4 |
|
|
|
1.6 |
|
Weighted-average discount rate
|
|
|
|
|
|
|
|
|
Operating leases
|
|
|
5.45 |
%
|
|
|
5.47 |
%
|
Finance leases
|
|
|
4.57 |
%
|
|
|
4.57 |
%
|
Operating and finance lease costs were as follows (in
thousands):
|
|
|
Three Months Ended March 31,
|
|
Lease Cost
|
Classification
|
|
2020
|
|
|
2019
|
|
|
|
|
(unaudited) |
|
|
(unaudited) |
|
Operating lease cost
|
Sales and marketing, general and
administrative
|
|
$ |
550 |
|
|
$ |
271 |
|
Finance lease cost:
|
|
|
|
|
|
|
|
|
|
Amortization of leased assets
|
Depreciation and amortization
|
|
|
181 |
|
|
|
96 |
|
Interest on lease liabilities
|
Interest expense, net
|
|
|
24 |
|
|
|
37 |
|
Total operating and finance lease
cost
|
|
$ |
755 |
|
|
$ |
404 |
|
Intangible Assets
Intangible assets consist of the following (in thousands):
|
|
March 31, 2020
(unaudited)
|
|
|
December 31, 2019
|
|
|
|
Cost
|
|
|
Accumulated
Amortization
|
|
|
Net
|
|
|
Cost
|
|
|
Accumulated
Amortization
|
|
|
Net
|
|
Distributor organizations
|
|
$ |
15,735 |
|
|
$ |
10,644 |
|
|
$ |
5,091 |
|
|
$ |
15,735 |
|
|
$ |
10,418 |
|
|
$ |
5,317 |
|
Trademarks and trade names
|
|
|
8,430 |
|
|
|
2,716 |
|
|
|
5,714 |
|
|
|
8,430 |
|
|
|
2,539 |
|
|
|
5,891 |
|
Customer relationships
|
|
|
10,442 |
|
|
|
6,587 |
|
|
|
3,855 |
|
|
|
10,442 |
|
|
|
6,413 |
|
|
|
4,029 |
|
Internally developed software
|
|
|
720 |
|
|
|
682 |
|
|
|
38 |
|
|
|
720 |
|
|
|
657 |
|
|
|
63 |
|
Non-compete agreement
|
|
|
277 |
|
|
|
29 |
|
|
|
248 |
|
|
|
277 |
|
|
|
11 |
|
|
|
266 |
|
Intangible assets
|
|
$ |
35,604 |
|
|
$ |
20,658 |
|
|
$ |
14,946 |
|
|
$ |
35,604 |
|
|
$ |
20,038 |
|
|
$ |
15,566 |
|
Amortization expense related to intangible assets was approximately
$620,000 and $670,000 for the three
months ended March 31, 2020 and
2019, respectively.
At March 31, 2020 and December 31, 2019, approximately $1,649,000
in trademarks from business combinations have been identified as
having indefinite lives.
Goodwill
Goodwill activity by reportable segment consists of the following
(in thousands):
|
|
Direct
Selling
|
|
|
Commercial Coffee
|
|
|
Commercial Hemp
|
|
|
Total
|
|
Balance at December 31, 2019
|
|
$ |
3,678 |
|
|
$ |
3,314 |
|
|
$ |
– |
|
|
$ |
6,992 |
|
Balance at March 31, 2020 (unaudited)
|
|
$ |
3,678 |
|
|
$ |
3,314 |
|
|
$ |
– |
|
|
$ |
6,992 |
|
- 21-
Note 6. Notes
Payable and Other Debt
Credit Note
In December 2018, CLR entered into
a credit agreement with Mr. Grover pursuant to which CLR borrowed
$5,000,000 from Mr. Grover and in exchange issued to him a
$5,000,000 credit note (the “Credit Note”). In addition, Siles, as
guarantor, executed a separate guaranty agreement. The Credit Note
is secured by CLR’s green coffee inventory, subordinate to certain
debt owed to Crestmark Bank and pari passu with certain holders of
notes issued by the borrowers of the company in 2014. At both March 31, 2020 and December 31, 2019, the outstanding principal
balance of the Credit Note was $5,000,000.
The Credit Note accrues interest at a rate of 8.00% per annum and
in accordance with the Credit Note is paid quarterly. The credit
note contains customary events of default including the Company or
Siles failure to pay its obligations, commencing bankruptcy or
liquidation proceedings, and breach of representations and
warranties. Upon the occurrence of an event of default, the unpaid
balance of the principal amount of the Credit Note together with
all accrued but unpaid interest thereon, may become, or may be declared to be, due and payable by Mr.
Grover and shall bear interest from the due date until such amounts
are paid at the rate of 10.00% per annum. In connection with the
credit agreement, the Company issued to Mr. Grover a four-year warrant to purchase
250,000 shares of its common stock, exercisable at $6.82 per share,
and a four-year
warrant to purchase 250,000 shares of its common stock, exercisable
at $7.82 per share.
In connection with the Credit Note, the Company also entered into
an advisory agreement with a third
party not affiliated with Mr.
Grover, pursuant to which the Company agreed to pay to the advisor
a 3.00% fee on the transaction with Mr. Grover and issued to the
advisor’s designee a four-year warrant to purchase
50,000 shares of the Company’s common stock, exercisable at $6.33
per share.
The Company recorded debt discounts of approximately $1,469,000
related to the fair value of warrants issued in the transaction and
$175,000 of transaction issuance costs both of which are amortized
to interest expense over the life of the Credit Note. The Company
recorded amortization of approximately $209,000 and $154,000
related to the debt discount and issuance cost during the
three months ended March 31, 2020 and 2019, respectively. At March 31, 2020 and December 31, 2019, the combined remaining
balance of the debt discounts and issuance cost was approximately
$706,000 and $915,000, respectively.
In December 2020, the Credit Note
became payable and due in accordance with its terms. CLR did
not make the payment due upon the
maturity date of the Credit Note. At the filing date of this
Quarterly Report on Form 10-Q, the
Company was in default of the terms of settlement of the Credit
Note and the Credit Note remains outstanding; however no formal demand for repayment has been
made.
2019 Promissory
Notes
In March 2019, the Company entered
into a two-year
secured promissory note (the “2019
Promissory Notes”) with two
accredited investors that had a substantial pre-existing
relationship with the Company pursuant to which the Company raised
cash proceeds in the aggregate of $2,000,000. The 2019 Promissory Notes bear interest at a rate
of 8.00% per annum and interest is paid quarterly in arrears with
all principal and unpaid interest due at maturity on March 18, 2021. The 2019 Promissory Notes are secured by all
equity in KII. At both March 31,
2020 and December 31, 2019,
the outstanding principal balance of the 2019 Promissory Notes was $2,000,000.
In conjunction with the 2019
Promissory Notes, the Company also issued 40,000 shares of the
Company’s common stock and five-year warrants to purchase
40,000 shares of the Company’s common stock. (See Note 10)
The Company recorded debt discounts of approximately $212,000
related to transaction issuance costs and $139,000 related to the
fair value of warrants issued in the transaction both of which are
amortized to interest expense over the life of the 2019 Promissory Notes. The Company recorded
amortization of approximately $43,000 and $5,000 related to the
debt discount and issuance cost related to the 2019 Promissory Notes during the three months ended March 31, 2020 and 2019, respectively. At March 31, 2020 and December 31, 2019, the combined remaining
balance of the debt discount and issuance costs was approximately
$185,000 and $228,000, respectively.
In February 2021, the Company
entered into amendment agreements extending the 2019 Promissory Notes and increasing the
interest rate. At the filing date, the Company was in default of
the terms of the amended agreements. (See Note 13)
- 22-
Mangless Note
In March 2020, the Company entered
into a securities purchase agreement with Daniel Mangless pursuant
to which the Company issued a senior secured promissory note in the
principal amount of $1,000,000 (the “Mangless Note”) which matured
in December 2020, bearing interest
at 18.00% per annum. In December
2020, the Company defaulted on the settlement of the Mangless
Note.
The Mangless Note provided the Company with an option to prepay at
any time without permission or penalty. The Mangless Note is
secured pursuant to the terms of a pledge and security agreement,
entered into by the Company and CLR with Mr. Mangless, whereby the
Mangless Note is secured by a first
priority lien granted by CLR in its rights under the pledge and
security agreement, by and between H&H, H&H Export and CLR
to receive certain payments (the “Mangless Pledge and Security
Agreement”).
In addition, the Company issued 50,000 shares of common stock in
connection with Mangless Note. (See Note 10)
The Company recognized debt discounts of approximately $65,000
resulting from the allocated portion of offering proceeds to the
separable common stock issuance. The debt discount was amortized to
interest expense over the term of the Mangless Note. During the
three months ended March 31, 2020, the Company recorded
approximately $2,000 of amortization related to the debt discounts.
At March 31, 2020, the remaining
balance of the debt discount was approximately $63,000.
In April 2021, the Company entered
into a settlement agreement with Mr. Mangless related to the
payment schedule of the Mangless Note issued in March 2020. In addition, as part of the
settlement agreement the Company issued Mr. Mangless 1,000,000
shares of common stock. (See Note 13)
2400 Boswell Mortgage
Note
The Company’s mortgage for its corporate office and warehouse in
Chula Vista, California, is payable over 25 years with an interest
rate set at the prime rate plus 2.50%. The lender will adjust the
interest rate on the first calendar
day of each change period. The Company and its Chief Executive
Officer and Chairman and Chief Operating Officer are
guarantors of the mortgage. On March 31,
2020 and December 31, 2019,
the interest rate was 7.25% and 7.50%, respectively. On March 31, 2020 and December 31, 2019, the balance on the
mortgage was approximately $3,122,000 and $3,143,000,
respectively.
The Company’s corporate office’s mortgage qualified for the
mortgage payment program for a period of six months under the Small Business
Administration (“SBA”) lenders program. (See Note 13)
Khrysos Mortgage Notes
In conjunction with the Company’s acquisition of Khrysos Global,
the Company assumed an interest only mortgage for properties
located in Mascotte, Florida in the amount of $350,000 and interest
paid monthly at a rate of 8.00% per annum. In September 2021, the mortgage was amended to
extend the maturity date by one
year to the earlier of September
2022 or the date of the sale of the property. In addition, the
Company assumed a mortgage of approximately $177,000 for properties
located in Clermont, Florida with all unpaid principal due in
June 2023 and interest paid monthly
at a rate of 7.00% per annum.
At March 31, 2020 and December 31, 2019, the aggregate outstanding
principal balance on the mortgages was approximately $521,000 and
$528,000, respectively.
In February 2019, KII purchased a
45-acre tract of land in Groveland, Florida for $750,000. The
Company paid $300,000 as a down payment and assumed a mortgage of
$450,000. All unpaid principal was due in February 2024 and interest was paid monthly
at a rate of 6.00% per annum. At March
31, 2020 and December 31,
2019, the remaining mortgage balance was approximately
$437,000 and $440,000, respectively.
In February 2021, the Company
determined that KII’s original plan for use of certain properties
was not viable for its future as
KII had shifted its focus back to its primary core business of
extraction of cannabinoids and the production of products for sale
with the cannabinoids. As a result, the Khrysos Mortgage Notes were
subsequently sold. (See Note 13)
Lending Agreements
In July 2018, the Company entered
into lending agreements with three
separate entities and received loans in the total amount of
$1,907,000, net of loan fees to be paid back over an eight-month period on a monthly basis.
Payments were made monthly and comprised of principal and accrued
interest with an effective interest rate between 15% and 20%.
The loans were paid in full in the first quarter of 2019.
M2C Purchase
Agreement
In March 2007, the Company entered
into an agreement to purchase certain assets of M2C Global, Inc., a Nevada corporation, for
$4,500,000. The agreement required payments totaling $500,000
in three installments during 2007,
followed by monthly payments in the amount of 10.00% of the sales
related to the acquired assets until the entire note balance is
paid. On March 31, 2020 and
December 31, 2019, the carrying
value of the liability was approximately $1,016,000 and $1,027,000,
respectively.
Other Notes
The Company’s other notes relate to loans for commercial vans at
CLR in the amount of $66,000 and $71,000 on March 31, 2020 and December 31, 2019, respectively, which expire
at various dates through 2023.
- 23-
Line of Credit
The Company’s loan and security agreement with Crestmark Bank
(“Crestmark”) provides for a line of credit related to accounts
receivables resulting from sales of certain products that includes
borrowings to be advanced against acceptable eligible inventory
related to CLR. Under the loan and security agreement the maximum
overall borrowing limit on the line of credit is $6,250,000. The
line of credit may not exceed an amount which is the lesser of
(a) $6,250,000 or (b) the sum of up (i) to 85% of the value of the
eligible accounts; plus, (ii) the lesser of $1,000,000 or 50% of
eligible inventory or 50% of the amount calculated in (i) above,
plus (iii) the lesser of $250,000 or eligible inventory or 75% of
certain specific inventory identified within the agreement.
The agreement contains certain financial and nonfinancial covenants
with which the Company must comply to maintain its borrowing
availability and avoid penalties. At the filing date of this
Quarterly Report on Form 10-Q, the
Company was not in compliance with
the covenants under the terms of the agreement.
In January 2022, the Company
entered into the second amendment
to the Crestmark loan and security agreement which reduced the
maximum overall borrowing limit on the line of credit to
$3,000,000. In February 2022, the
Company received a notice of default related to the loan and
security agreement from Crestmark. In April 2022, The Company entered into a
forbearance agreement with Crestmark. (See Note 13)
The outstanding principal balance of the line of credit bears
interest based upon a 360-day year
with interest charged for each day the principal amount is
outstanding including the date of actual payment. The interest rate
is a rate equal to the prime rate plus 2.50% with a floor of 6.75%.
On March 31, 2020 and December 31, 2019, the interest rate was
6.75% and 7.25%, respectively. In addition, other fees are incurred
for the maintenance of the loan in accordance with the agreement.
Other fees may be incurred in the
event the minimum loan balance of $2,000,000 is not maintained. The agreement was effective
beginning in November 2017 and will
continue to be effective until June 30,
2022, the termination date agreed upon in the forbearance
agreement entered in April
2022.
The Company and Stephan Wallach entered into a corporate guaranty
and personal guaranty, respectively, with Crestmark guaranteeing
payments in the event that the Company’s commercial coffee segment
CLR were to default. In addition, David Briskie, the Company’s
president and chief financial officer, personally entered into a
guaranty of validity representing the Company’s financial
statements so long as the indebtedness is owed to Crestmark,
maintaining certain covenants and guarantees.
The Company’s outstanding line of credit liability with Crestmark
was approximately $2,025,000 and $2,011,000 at March 31, 2020 and December 31, 2019, respectively.
Note 7. Convertible Notes
Payable
Total convertible notes payable, net of debt discount outstanding
consisted of the amount set forth in the following table (in
thousands):
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited) |
|
|
|
|
6.00% Convertible Notes
(2019 PIPE Notes), principal
|
|
$ |
3,090 |
|
|
$ |
3,090 |
|
Debt discounts
|
|
|
(331 |
)
|
|
|
(415 |
)
|
Carrying value of 2019 PIPE Notes
|
|
|
2,759 |
|
|
|
2,675 |
|
|
|
|
|
|
|
|
|
|
8.00% Convertible Notes
(2014 PIPE Notes), principal
|
|
|
25 |
|
|
|
25 |
|
Debt discounts
|
|
|
– |
|
|
|
– |
|
Carrying value of 2014 PIPE Notes
|
|
|
25 |
|
|
|
25 |
|
Total carrying value of convertible notes payable
|
|
$ |
2,784 |
|
|
$ |
2,700 |
|
Unamortized debt discounts and issuance costs are included with
convertible notes payable, net of debt discount on the consolidated
balance sheets.
2019 PIPE Notes
Between February and July 2019, the Company closed five tranches related to the 2019 private placement debt offering,
pursuant to which the Company offered for sale up to $10,000,000 in
principal amount of notes (the “2019 PIPE Notes”), with each investor
receiving 2,000 shares of common stock for each $100,000 invested.
- 24-
The Company entered into subscription agreements with thirty-one accredited investors, that had a
substantial pre-existing relationship with the Company, pursuant to
which the Company issued the 2019
PIPE Notes in the aggregate principal amount of $3,090,000. Each
2019 PIPE Note matures 24 months after issuance, bears interest at a
rate of 6.00% per annum which is paid quarterly, and the
outstanding principal is convertible into shares of common stock at
any time after the 180th day
anniversary of the issuance of the 2019 PIPE Notes, at a conversion price of
$10.00 per share, subject to adjustment for stock splits, stock
dividends and reclassification of the common stock. The 2019 PIPE Notes are secured by all equity in
KII. At March 31, 2020 and
December 31, 2019, the 2019 PIPE Notes remained outstanding.
Upon issuance of the 2019 PIPE
Notes, the Company recognized debt discounts of approximately
$671,000, resulting from the allocated portion of offering proceeds
to the separable common stock issuance. The debt discount will be
amortized to interest expense over the term of the 2019 PIPE Notes. During the three months ended March 31, 2020, the Company recorded
approximately $84,000 of amortization related to the debt
discounts. At March 31, 2020 and
December 31, 2019, the remaining
balance of the debt discount was approximately $331,000 and
$415,000, respectively.
In February and March 2021, the 2019 PIPE Notes that were maturing were
extended by one year by way of an
amendment with certain note holders of an aggregate $2,440,000 in
principal amount. At the filing date of this Quarterly Report on
Form 10-Q, the Company was in
default of the terms of settlement set forth in the amendments.
(See Note 13)
2014 PIPE Notes
Between July and September 2014, the Company entered into note
purchase agreements (the “2014 PIPE
Note” or “2014 PIPE Notes”) related
to its private placement offering (the “2014 private placement”) with seven accredited investors pursuant to which
the Company raised aggregate gross proceeds of $4,750,000 and sold
units consisting of five year senior secured
convertible 2014 PIPE Notes in the
aggregate principal amount of $4,750,000 that were convertible into
678,568 shares of the Company’s common stock, at a conversion price
of $7.00 per share, and warrants to purchase 929,346 shares of
common stock at an exercise price of $4.60 per share. The
2014 PIPE Notes bear interest at a
rate of 8.00% per annum and interest was paid quarterly in
arrears.
The Notes are secured by Company pledged assets and rank senior to
all debt of the Company other than certain senior debt that has
been previously identified as senior to the convertible notes.
Additionally, Stephan Wallach, the Company’s Chief Executive
Officer, has also personally guaranteed the repayment of the Notes,
subject to the terms of a Guaranty Agreement executed by him with
the investors. In addition, Mr. Wallach has agreed not to sell, transfer or pledge 1.5 million
shares of the common stock that he owns so long as his personal
guaranty is in effect.
In September 2019, the Company
extended the maturity date of one
holder of a 2014 PIPE Note with a
balance of $25,000 for one year,
with interest being paid under the original terms of 8.00% per
annum and interest paid quarterly in arrears. At March 31, 2020 and December 31, 2019, the outstanding balance of
the 2014 PIPE Note was $25,000. All
other 2014 PIPE Notes have been
settled.
In 2014, the Company initially
recorded debt discounts of $4,750,000 related to the beneficial
conversion feature and related detachable warrants. The beneficial
conversion feature discount and the detachable warrants discount
are amortized to interest expense over the life of the 2014 PIPE Notes. The unamortized debt
discounts recognized with the debt exchange was approximately
$679,000. The Company recorded approximately $31,000 of
amortization of the debt discounts during the three months ended March 31, 2019. At December 31, 2019, the debt discounts
relating to the 2014 PIPE Notes
were fully amortized.
In 2014, the Company paid
approximately $490,000 in expenses including placement
agent fees relating to issuance costs with the 2014 private placement. The unamortized
issuance costs recognized with the debt exchange was approximately
$63,000. The issuance costs were amortized to interest expense over
the term of the 2014 PIPE Notes.
The Company recorded approximately $3,000 of amortization of the
issuance costs during the three
months ended March 31, 2019. At
December 31, 2019, all issuance
costs relating to the 2014 private
placement and debt exchange were fully amortized.
Note 8. Derivative
Liability
Warrants
The estimated fair value of the outstanding warrant derivative
liabilities was $53,000 and $1,542,000 at March 31, 2020 and December 31, 2019, respectively.
Increases or decreases in the fair value of the derivative
liability are included as a component of total other expense in the
accompanying consolidated statements of operations for the
respective period. The changes to the derivative liability for
warrants resulted in a decrease of $1,489,000 and $1,486,000 for
the three months ended March 31, 2020 and 2019, respectively.
- 25-
The estimated fair value of the warrants was computed at March 31, 2020 and December 31, 2019 using the Monte Carlo
option pricing model with the following assumptions:
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited) |
|
|
|
|
Stock price volatility
|
|
|
96.7 |
% |
|
|
64.10 |
% |
Risk-free interest rates
|
|
|
0.12% |
– |
0.16 |
% |
|
|
1.59% |
– |
1.60 |
% |
Annual dividend yield
|
|
|
- |
|
|
|
– |
|
Expected life (in years)
|
|
|
0.3 |
– |
0.7 |
|
|
|
0.6 |
– |
1.0 |
|
In addition, management assessed the probabilities of future
financing assumptions in the valuation models.
Note 9. Fair Value of
Financial Instruments
The following table details the fair value measurement within the
fair value hierarchy of the Company’s financial instruments, which
includes the Level 3 liabilities
(in thousands):
|
|
Fair Value at March 31, 2020
(unaudited)
|
|
|
|
Total
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent acquisition debt, current portion
|
|
$ |
1,382 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
1,382 |
|
Contingent acquisition debt, less current portion
|
|
|
6,759 |
|
|
|
- |
|
|
|
- |
|
|
|
6,759 |
|
Warrant derivative liability
|
|
|
53 |
|
|
|
- |
|
|
|
- |
|
|
|
53 |
|
Total derivative liabilities
|
|
$ |
8,194 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
8,194 |
|
|
|
Fair Value at December 31, 2019
|
|
|
|
Total
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent acquisition debt, current portion
|
|
$ |
1,263 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
1,263 |
|
Contingent acquisition debt, less current portion
|
|
|
7,348 |
|
|
|
- |
|
|
|
- |
|
|
|
7,348 |
|
Warrant derivative liability
|
|
|
1,542 |
|
|
|
- |
|
|
|
- |
|
|
|
1,542 |
|
Total derivative liabilities
|
|
$ |
10,153 |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
10,153 |
|
The following table reflects the activity for the Company’s warrant
derivative liability associated with the Company’s private
placements measured at fair value using Level 3 inputs (in thousands):
Balance at December 31, 2019
|
|
$ |
1,542 |
|
Adjustments to estimated fair value
|
|
|
(1,489 |
)
|
Balance at March 31, 2020 (unaudited)
|
|
$ |
53 |
|
The following table reflects the activity for the Company’s
contingent acquisition liabilities measured at fair value using
Level 3 inputs (in thousands):
Balance at December 31, 2019
|
|
$ |
8,611 |
|
Liabilities settled
|
|
|
(109 |
)
|
Adjustments to liabilities included in net loss
|
|
|
(361 |
)
|
Balance at March 31, 2020 (unaudited)
|
|
$ |
8,141 |
|
The weighted-average discount rate used to determine the fair value
of contingent acquisition debt was 18.50% and 18.42% at March 31, 2020 and December 31, 2019, respectively.
Note 10. Stockholders’
Equity
The Company’s Certificate of Incorporation, as amended, authorizes
the issuance of two classes of
stock to be designated “common stock” and “preferred stock”.
- 26-
At March 31, 2020, the total number
of shares of stock which the Company has authority to issue was
50,000,000 shares of common stock, par value $0.001 per share and
5,000,000 shares of preferred stock, par value $0.001 per share, of
which (i) 161,135 shares was designated as Series A preferred stock
(ii) 1,052,631 was designated as Series B preferred stock, (iii)
700,000 was designated as Series C preferred stock and (iv) 650,000
was designated as Series D preferred stock.
The Company’s common stock is traded on the OTC Pink Market
operated by OTC Markets under the symbol “YGYI”. From June 2017 until November 2020, the Company’s common stock was
traded on Nasdaq Capital Market under the symbol “YGYI.” From
June 2013 until June 2017, the Company’s common stock was
traded on the OTCQX Marketplace operated by OTC Markets under the
symbol “YGYI”. Previously, the common stock was quoted on the OTC
Markets OTC Pink market system under the symbol “JCOF”.
The Company’s 9.75% Series D Cumulative Redeemable Perpetual
Preferred Stock, $0.001 par value is traded on OTC Pink market
operated by OTC Markets Group under the symbol “YGYIP”.
Shelf Registration
In May 2018, the SEC declared the
Company’s shelf registration statement on Form S-3 effective to register shares of the
Company’s common stock for sale of up to $75,000,000 giving the
Company the opportunity to raise funding when considered
appropriate at prices and on terms to be determined at the time of
any such offerings. The Company’s ability to sell securities
registered on its registration statement on Form S-3 (the “Shelf”) was limited until such time
the market value of its voting securities held by non-affiliates is
$75 million or more. At December 31,
2019, the Company raised net proceeds under the Shelf in the
aggregate of approximately $12,371,000 from the issuance of the
Company’s preferred stock series D offering and the ATM noted
below. The Company is no longer
eligible to use the Shelf.
Common Stock
At March 31, 2020 and December 31, 2019 there were 30,712,432 and
30,274,601 shares of common stock outstanding, respectively. The
holders of the common stock are entitled to one vote for each share
held at all meetings of stockholders (and written actions in lieu
of meetings).
Stock Offerings
March 2020 Private
Placement
In March 2020, the Company closed
one tranche of its March 2020 private placement debt offering,
pursuant to which the Company offered of up to an aggregate of
$5,000,000 in principal amount together with up to 250,000 shares
of common stock with each investor receiving 50,000 shares of
common stock for each $1,000,000
invested. In March 2020, the
Company entered into a securities purchase agreement with Daniel
Mangless pursuant to which the Company received proceeds of
$1,000,000 and issued the Mangless Note. Mr. Mangless received
50,000 shares of the Company’s common stock in connection with his
investment.
In April 2021, the Company entered
into a settlement agreement with Daniel Mangless related to the
Mangless Note issued in March 2020.
In addition, pursuant to the settlement agreement, the Company
issued Mr. Mangless 1,000,000 shares of its common stock. (See Note
13)
2019 Share Purchase
Agreements
In June 2019, the Company entered
into a securities purchase agreement with Daniel Mangless pursuant
to which the Company sold 250,000 shares of common stock at an
offering price of $5.50 per share. There were no fees related to
this agreement. The Company received proceeds of $1,375,000.
In February 2019, the Company
entered into a securities purchase agreement with Daniel Mangless
pursuant to which the Company sold 250,000 shares of common stock
at an offering price of $7.00 per share. Pursuant to the purchase
agreement, the Company also issued to Mr. Mangless a three-year warrant to purchase
250,000 shares of common stock at an exercise price of $7.00. The
Company received gross proceeds of $1,750,000. Consulting fees to
the placement agent for arranging the purchase agreement included
the issuance of 5,000 shares of restricted shares of the Company’s
common stock with a fair value of $7.00 per share, and three-year warrants to purchase
100,000 shares of common stock expiring in February 2022 which were priced at $10.00 per
share. The Company used the Black-Scholes option-pricing model to
estimate the fair value of the warrants issued to the selling agent
to be $324,000 at the time of issuance as direct issuance costs and
recorded in equity. No cash commissions were paid.
- 27-
2019 Promissory Notes
In March 2019, the Company entered
into 2019 Promissory Notes and
raised cash proceeds in the aggregate of $2,000,000. In
consideration of the 2019
Promissory Notes, the Company issued 20,000 shares of common stock
and five-year
warrants to purchase 20,000 shares of common stock at a price per
share of $6.00 for each $1,000,000
invested. The Company issued in the aggregate 40,000 shares of
common stock and 40,000 warrants with the 2019 Promissory Notes. The Company used
the Black-Scholes option-pricing model to estimate the aggregate
fair value of the warrants issued to be $138,000 at the time of
issuance as direct issuance costs and recorded as a debt discount
and is being amortized as expense over the life of the 2019 Promissory Notes. The aggregate fair
value of the shares issued was based on the closing price of the
Company’s common stock on the closing date was approximately
$212,000 was recorded as a debt discount and was amortized as
expense over the life of the 2019
Promissory Notes.
In February 2021, the Company
entered into amendment agreements extending the 2019 Promissory Notes and increasing the
interest rate. At the filing date, the Company was in default of
the terms of the amended agreements. (See Note 13)
2019 Private Placement -
Convertible Notes
Between February and July 2019, the Company closed five tranches related to the 2019 January
private placement debt offering, pursuant to which the Company
offered the 2019 PIPE Notes, with
each investor receiving in addition to the 2019 PIPE Notes, 2,000 shares of common stock
for each $100,000 invested. The
Company issued an aggregate of 61,800 shares of common stock as a
result of the 2019 private
placement. The placement agent received 15,450 shares of common
stock for the closed tranches. The aggregate fair value of the
shares issued based on the closing price of the Company’s common
stock on the closing date was approximately $451,000 which was
recorded as a debt discount and was amortized as expense over the
life of the promissory notes.
In February and March 2021, the 2019 PIPE Notes that were maturing were
extended by one year by way of an
amendment with certain note holders of an aggregate $2,440,000 in
principal amount. In connection with the foregoing, the Company
issued to the holders of the amended 2019 PIPE Notes an aggregate of 366,000
shares of its restricted common stock as an inducement to enter
into the amendments. At the filing date of this Quarterly Report on
Form 10-Q, the Company was in
default of the terms of settlement set forth in the amendments.
(See Note 13)
At-the-Market Equity Offering Program
In January 2019, the
Company entered into the “ATM agreement with the Benchmark
Company LLC (“Benchmark”) pursuant to which the Company may sell from time to time, at the Company’s
option, shares of its common stock through Benchmark as sales
agent, for the sale of up to $60,000,000 of shares of the Company’s
common stock. The Company is not
obligated to make any sales of common stock under the ATM agreement
and the Company cannot provide any assurances that it will continue
to issue any shares pursuant to the ATM agreement. During the year
ended December 31, 2019, the
Company sold 17,524 shares of common stock under the ATM agreement
and received net proceeds of approximately $102,000. The Company
paid the Benchmark 3.0% commission of the gross sales proceeds. The
Company is not currently eligible
to register the offer and sale of the Company’s securities using a
registration statement on Form S-3
and therefore cannot make sales under the ATM agreement until such
time that the Company once again becomes S-3 eligible.
2018 Private Placement
Between August 2018 and October 2018, the Company completed its
2018 private placement and entered
into securities purchase agreements with nine investors with whom the Company had a
substantial pre-existing relationship pursuant to which the Company
sold an aggregate of 630,526 shares of common stock at an offering
price of $4.75 per share. In addition, the Company issued the
investors an aggregate of 150,000 additional shares of common stock
as an advisory fee and issued the investors three-year warrants to purchase
an aggregate of 630,526 shares of common stock at an exercise price
of $4.75 per share. The fair value of the warrants as issuance
date was approximately $1,689,000. During the year ended December 31, 2019, investors exercised a
portion of the 2018 warrants into
182,106 shares of common stock. The 2018 warrants to purchase 448,420 shares of
common stock remained outstanding at March 31, 2020 and December 31, 2019.
The Company adopted ASU No.
2017-11 effective January 1, 2019 and determined that the
2018 warrants should no longer be classified as a derivative. As a
result of the adoption and subsequent change in classification of
the 2018 warrants, the Company
reclassed approximately $1,494,000 of warrant derivative liability
to equity.
- 28-
2014 Convertible Note –
Debt Exchange
In October 2018, the Company
entered into an agreement with Carl Grover to exchange all amounts
owed under the 2014 Note held by
him in the principal amount of $4,000,000 which matured in
July 2019, for 747,664 shares of
the Company’s common stock at a conversion price of $5.35 per
share, and a four-year warrant to purchase
631,579 shares of common stock at an exercise price of $4.75 per
share. The agreement was subject to shareholder approval which was
received in December 2018. The
warrant to purchase 631,579 shares of common stock remained
outstanding at March 31, 2020 and
December 31, 2019.
A FINRA broker dealer acted as the Company’s advisor in connection
with the debt exchange. Upon the closing of the debt exchange, the
Company subsequently received shareholder approval to issue the
broker dealer 30,000 shares of common stock, a four-year warrant to purchase
80,000 shares of common stock at an exercise price of $5.35 per
share and a four-year
warrant to purchase 70,000 shares of common stock at an exercise
price of $4.75 per share. The warrants to purchase an
aggregate 150,000 shares remained outstanding at March 31, 2020 and December 31, 2019.
Preferred Stock
Series A Preferred Stock
The Company had 161,135 shares of Series A preferred stock
outstanding at both March 31, 2020
and December 31, 2019 and accrued
dividends of approximately $153,000 and $150,000, respectively.
The holders of the Series A preferred stock are entitled to receive
a cumulative dividend at a rate of 8.00% per year, payable annually
either in cash or shares of the Company's common stock at the
Company's election. Each share of Series A preferred stock is
convertible into common stock at a conversion rate of one-tenth of a share. The holders of Series A
preferred stock are entitled to receive payments upon liquidation,
dissolution or winding up of the Company before any amount is paid
to the holders of common stock. The holders of Series A preferred
stock have no voting rights, except
as required by law.
Series B Preferred Stock
In March 2018, the Company
completed the Series B offering, pursuant to which the Company sold
381,173 shares of Series B preferred stock at an offering price of
$9.50 per share. Each share of Series B preferred stock is
initially convertible at any time, in whole or in part, at the
option of the holders, at a conversion price of $4.75 per share,
into 2 shares of common stock and automatically converts into 2
shares of common stock on its two-year anniversary of issuance.
In connection with the Series B offering, the Company issued the
placement agent 38,117 warrants as compensation, exercisable at
$5.70 per share and expire in February
2023. The Company determined that the warrants should be
classified as equity instruments and used Black-Scholes to estimate
the fair value of the warrants issued to the placement agent of
$75,000 at the issuance date. At March
31, 2020 and December 31,
2019, 6,098 warrants issued to the placement agent remained
outstanding.
The Company had 129,332 shares of Series B preferred stock
outstanding at December 31, 2019.
In March 2020, all outstanding
shares of Series B preferred stock automatically converted into 2
shares of common stock on the two-year anniversary date of the issuance of
the Series B preferred stock, pursuant to the automatic conversion
feature of the Series B preferred stock. A total of 129,332 shares
of Series B preferred stock outstanding automatically converted
into 258,664 shares of common stock.
During the year ended December 31,
2019, the Company received notice of conversion for 105 shares
of Series B preferred stock which converted to 210 shares of common
stock.
Pursuant to the certificate of designation, the Company paid
cumulative dividends on the Series B preferred stock from the date
of original issue at a rate of 5.0% per annum payable
quarterly in arrears on or about the last day of March, June,
September and December of each year, ending in March 2020.
At December 31, 2019, accrued
dividends for Series B preferred stock were approximately $15,000.
During the three months ended
March 31, 2020 and 2019, a total of approximately $32,000 and
$11,000, respectively, of dividends was paid to the holders of the
Series B preferred stock. All dividends related to the Series B
preferred stock were paid in full at March 31, 2020. The Series B preferred stock
ranked senior to the Company’s outstanding Series A preferred stock
and the common stock with respect to dividend rights and rights
upon liquidation, dissolution or winding up. Holders of the Series
B preferred stock had no voting
rights.
- 29-
Series C Preferred Stock
In connection with the Series C offering in 2018, the Company issued the placement agent
116,867 warrants as compensation, exercisable at $4.75 per share.
At December 31, 2019, no Series C
preferred stock remained outstanding. During the year ended
December 31, 2019, the placement
agent exercised a portion of the warrants into 99,143 shares of
common stock. The remaining warrants expire in December 2020.
Series D Preferred Stock
In September and December 2019, the Company closed two tranches of its Series D offering (the
“Series D Offering”), pursuant to which the Company issued and sold
a total of 578,898 shares of its 9.75% Series D cumulative
preferred stock at a weighted average price to the public of $24.05
per share, less underwriting discounts and commissions, pursuant to
the terms of the underwriting agreements that the Company entered
into with Benchmark, as representative of the several underwriters.
The 578,898 shares of Series D preferred stock that were sold
included 43,500 shares sold pursuant to the overallotment option
that the Company granted to the underwriters. At December 31, 2019, 36,809 overallotment
shares were unissued and available for purchase by the underwriters
within 45 days from December 17, 2019.
In January 2020, the Company issued
an additional 11,375 shares of Series D preferred stock upon the
partial exercise by the underwriters in the Company’s public
offering of Series D preferred stock of the overallotment option
granted to such underwriters. The overallotment shares were sold at
a price to the public of $22.75 per share, generating additional
gross proceeds of approximately $259,000.
The Series D preferred stock was approved for listing on the Nasdaq
Capital Market under the symbol “YGYIP,” and trading the Series D
preferred stock on Nasdaq commenced in September 2019. The net proceeds to the
Company from the Series D Offering were approximately $12,269,000
after deducting underwriting discounts and commissions and expenses
which were paid by the Company.
At March 31, 2020, a total of
650,000 shares of the preferred stock was designated as Series D
preferred stock. At March 31, 2020,
the Company has available for issuance an additional 59,727 shares
of Series D preferred stock.
The Series D preferred stock does not have a stated maturity date and is
not subject to any sinking fund or
mandatory redemption provisions. The holders of the Series D
preferred stock are entitled to cumulative dividends from the
first day of the calendar month in
which the Series D preferred stock is issued and payable on the
fifteenth day of each calendar
month, when, as and if declared by the Company's board of
directors. The Company’s board of directors has declared an annual
cash dividend of $2.4375 per share, or a monthly dividend of
$0.203125 per share, on the Series D preferred stock.
At March 31, 2020 and December 31, 2019, accrued dividends were
approximately $120,000 and $118,000, respectively. During the
three months ended March 31, 2020, the Company paid $358,000 in
cash dividends to holders of Series D preferred stock. At
March 31, 2020, accrued dividends
payable to holders of record at March
31, 2020 were paid in April
2020.
At March 31, 2020 and December 31, 2019, the Company had 590,273
and 578,898 shares, respectively, of Series D preferred stock
outstanding.
Upon liquidation, dissolution or winding up of the Company, each
holder of Series D preferred stock would be entitled to receive a
distribution, to be paid in an amount equal to $25.00 per share
held by the holders of Series D preferred stock, plus all accrued
and unpaid dividends in preference to any distribution or payments
made or any asset distributed to the holders of common stock, the
Series A preferred stock, the Series B preferred stock, the Series
C preferred stock or any other class or series of stock ranking
junior to the Series D preferred stock.
The Series D preferred stock is not
redeemable by the Company prior to September 23, 2022, except upon a change of
control (as defined in the certificate of designations). On and
after such date, the Company may,
at its option, redeem the Series D preferred stock, in whole or in
part, at any time or from time to time, for cash at a redemption
price equal to $25.00 per share, plus any accumulated and unpaid
dividends to, but not including,
the redemption date. Upon the occurrence of a change of control,
the Company may, at its option,
redeem the Series D preferred stock, in whole or in part, within
120 days after the first date on which such change of control
occurred, for cash at a redemption price of $25.00 per share, plus
any accumulated and unpaid dividends to, but not including, the redemption
date. Holders of the Series D preferred stock generally have
no voting rights.
- 30-
Advisory Agreements
The Company records the fair value of common stock issued in
conjunction with advisory service agreements based on the closing
stock price of the Company’s common stock on the measurement date.
The stock issuance expense associated with the amortization of
advisory fees was recorded as equity compensation expense and was
included in general and administrative expense on the Company’s
consolidated statements of operations.
Capital Market Solutions, LLC
In July 2018, the Company entered
into an agreement with Capital Market Solutions, LLC (“Capital
Market”), pursuant to which Capital Market agreed to provide
investor relations services for a period of 18 months in exchange for 100,000 shares of
restricted common stock which were issued in advance of the service
period. In addition, the Company agreed to pay a cash base fee
of $300,000 of which $50,000 was paid in August 2018 and the remaining balance was to
be paid monthly in the amount of $25,000. The Company subsequently
extended the term of the Capital Market agreement for an additional
24 months through December 31, 2021. The Company also issued an
additional 100,000 shares of restricted common stock to Capital
Market in advance of the service period and paid $125,000 for
additional fees. The fair value of the shares issued was
approximately $1,226,000.
In January 2019, the Capital Market
agreement was amended pursuant to which the aggregate base fee
increased to $525,000 and the Company issued an additional 75,000
of restricted common stock, with a fair value of $417,000. In
addition, the Company issued to Capital Market a four-year warrant to purchase
925,000 shares of the Company’s common stock at $6.00 per share,
vesting 50% at issuance, 25% vesting in January 2020 and 25% vesting in January 2021.
During the three months ended
March 31, 2020 and 2019, the Company recorded expense
of approximately $129,000 in connection with amortization of
the stock issuance expense. During the three months ended March 31, 2019, the
Company recorded expense of approximately $50,000 in
connection with the base fee. During the three months ended March 31, 2020 and 2019, the Company recorded expense
of approximately $92,000 and $1,656,000, respectively, in
connection with amortization of equity issuance expense related to
fair value of the vested portion of the warrant.
Corinthian Partners, LLC
In August 2019, the Company issued
600 shares of restricted common stock to Corinthian Partners, LLC,
the initial placement agent for the issuance of the 2018 warrants which represented 10% of the
shares issued to certain investors. The fair value of the shares
issued of approximately $3,000 was fully expensed in 2019.
Greentree Financial Group, Inc.
In March 2018, the Company entered
into an agreement with Greentree Financial Group,
Inc. (“Greentree”), pursuant to which Greentree agreed to
provide investor relations services through December 31, 2019 in exchange for 75,000
shares of restricted common stock which were issued in advance of
the service period. The fair value of the shares issued was
approximately $311,000. During the three months ended March 31, 2019, the
Company recorded expense of approximately $44,000 in
connection with amortization of the stock issuance.
I-Bankers Securities Incorporated
In April 2019, the Company entered
into an agreement with I-Bankers Securities Incorporated
(“I-Bankers”), pursuant to which I-Bankers agreed to provide
financial advisory services for a period of twelve months ending in March 2020 in exchange for 100,000 shares of
restricted common stock which were issued in advance of the service
period. The fair value of the shares issued was approximately
$571,000. During the three
months ended March 31,
2020, the Company recorded expense of approximately
$143,000 in connection with amortization of the stock issuance.
In addition, the Company agreed to pay in cash a base fee for debt
arrangements and equity offerings in conjunction with any
transactions I-Bankers closes with the Company in accordance with
the agreement. The Company did not
engage in any financing activity with I-Bankers through March 31, 2020.
- 31-
Ignition Capital, LLC
In April 2018, the Company entered
into an agreement with Ignition Capital,
LLC (“Ignition”), pursuant to which Ignition agreed to provide
investor relations services through December 31, 2019 in exchange for 50,000
shares of restricted common stock which were issued in advance of
the service period. The fair value of the shares issued was
approximately $208,000. During the three months ended March 31, 2019, the
Company recorded expense of approximately $30,000 in
connection with amortization of the stock issuance.
In March 2019, the Ignition
agreement was amended to provide additional compensation of 55,000
shares of the Company’s common stock for advisory fees and
additionally 5,000 shares of the Company’s common stock were issued
in conjunction with one of the
Company’s equity transactions. Under the amended Ignition
agreement, the Company also issued a warrant convertible upon
exercise of 100,000 shares of the Company’s common stock
exercisable at $10.00 per share for a period of three years for services provided
by Ignition at the amendment date. The fair value of the shares
issued was approximately $384,000 and the fair value of the warrant
issued was approximately $414,000 and was fully expensed as equity
issuance cost and recorded as equity in 2019.
Ivan Gandrud Chevrolet, Inc.
In March 2020, the Company entered
into an agreement with Ivan Gandrud Chevrolet, Inc. (“IGC”),
pursuant to which IGC agreed to provide consulting services for the
Company’s commercial hemp segment in exchange for 125,000 shares of
restricted common stock which were issued as fully earned. The
fair value of the shares issued was approximately $158,000. In
addition, the Company issued a 5-year warrant exercisable for
250,000 shares of the Company’s common stock at an exercise price
of $4.75. The warrant is deemed fully earned. The fair value of the
warrant issued was approximately $167,000. During the
three months ended March 31, 2020, the Company fully
amortized $325,000 of the issuance costs in connection this
agreement.
IGC is 100% owned by Daniel Mangless, who was the beneficial owner
of in excess of 5% of the Company’s
outstanding common stock at March 31,
2020.
The Benchmark Company, LLC
In August 2019, the board of
directors approved the issuance of 20,000 shares of restricted
common stock to Benchmark for investment banking services provided
to the Company. The fair value of shares issued was approximately
$91,000 and was fully expensed in 2019.
Warrants
At March 31, 2020 and December 31, 2019, warrants to purchase
6,488,182 and 6,238,182, respectively, of shares of the
Company's common stock at prices ranging from $2.00 to $10.00
were outstanding. At March 31,
2020, 6,314,743 warrants were exercisable and expire at
various dates through March 2025
and have a weighted average remaining term of approximately
1.6 years and are included in the table below.
The intrinsic value of the outstanding warrants based on the
Company’s closing stock prices at March
31, 2020 and December 31, 2019
was approximately $0 and $95,000, respectively.
The Company uses a combination of option-pricing models to estimate
the fair value of the warrants including the Monte Carlo, Lattice
and Black-Scholes.
A summary of the warrant activity is presented in the following
table:
|
|
Number of
Warrants
|
|
Outstanding at December 31, 2019
|
|
|
6,238,182 |
|
Issued
|
|
|
250,000 |
|
Outstanding at March 31, 2020 (unaudited)
|
|
|
6,488,182 |
|
Stock-based Compensation
Stock-based compensation expense related to stock options and
restricted stock units included in the consolidated statements of
operations was charged as follows (in thousands):
|
|
Three Months Ended March 31,
|
|
|
|
2020
|
|
|
2019
|
|
|
|
(unaudited) |
|
|
(unaudited) |
|
Cost of revenues
|
|
$ |
5 |
|
|
$ |
77 |
|
Sales and marketing
|
|
|
31 |
|
|
|
497 |
|
General and administrative
|
|
|
224 |
|
|
|
10,770 |
|
Total stock-based compensation
|
|
$ |
260 |
|
|
$ |
11,344 |
|
- 32-
Stock Options
A summary of the Plan stock option activity for the three months ended March 31, 2020 is presented in the following
table:
|
|
Number of
Shares
|
|
|
Weighted
Average
Exercise Price
|
|
|
Weighted
Average
Remaining Contract Life (years)
|
|
|
Aggregate
Intrinsic
Value
(in thousands)
|
|
Outstanding December 31, 2019
|
|
|
4,637,642 |
|
|
$ |
5.63 |
|
|
|
7.8 |
|
|
$ |
- |
|
Granted
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
Canceled / expired
|
|
|
(5,718 |
)
|
|
|
4.32 |
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
- |
|
Outstanding March 31, 2020 (unaudited)
|
|
|
4,631,924 |
|
|
$ |
5.63 |
|
|
|
7.6 |
|
|
$ |
- |
|
Exercisable March 31, 2020 (unaudited)
|
|
|
4,188,717 |
|
|
$ |
5.73 |
|
|
|
7.6 |
|
|
$ |
- |
|
The weighted-average fair value per share of the granted stock
options for the three months ended
March 31, 2019 was approximately
$4.26. There were no options granted during the three months ended March 31, 2020.
At March 31, 2020, there was
approximately $1,109,000 of total unrecognized compensation expense
related to unvested stock options granted under the 2012 Plan. The expense is expected to be
recognized over a weighted-average period of 1.6 years.
Restricted Stock Units
In August 2019, the Company issued
50,000 restricted stock units to one of its consultants. Vesting occurs
monthly over a three-year period with the
first vesting period commencing
one month from the grant date. The
fair value of the restricted stock units issued to the consultant
was based on the grant date closing stock price of $4.55 and is
recognized as stock-based compensation expense over the vesting
term of the award.
In August 2017, the Company issued
restricted stock units for an aggregate of 500,000 shares of common
stock to its employees and consultants. These shares of common
stock will be issued upon vesting of the restricted stock units.
Full vesting occurs on the sixth-year anniversary of the grant date,
with 10% vesting on the third-year,
15% on the fourth-year, 50% on the
fifth-year and 25% on the
sixth-year anniversary of the
vesting commencement date. The fair value of each restricted stock
unit issued to employees was based on the closing price on the
grant date of $4.53 and restricted stock units issued to
consultants were revalued with the closing stock price at each
change in financial period.
The Company adopted ASU 2018-07 on
January 1, 2019 and the stock-based
compensation expense for non-employee grants was based on the
closing price of the Company’s common stock of $5.72 per share on
December 31, 2018, which was the
last business day before we adopted ASU 2018-07.
A summary of restricted stock unit activity is presented in the
following table:
|
|
Number of Shares
|
|
Balance at December 31, 2019
|
|
|
451,944 |
|
Issued
|
|
|
- |
|
Canceled
|
|
|
(5,000 |
)
|
Vested
|
|
|
(4,167 |
)
|
Balance at March 31, 2020 (unaudited)
|
|
|
442,777 |
|
At March 31, 2020, total
unrecognized stock-based compensation expense related to restricted
stock units to employees and consultants was approximately
$1,230,000, which will be recognized over a weighted average period
of 3.4 years.
- 33-
Note 11. Commitments and
Contingencies
Credit Risk
The Company maintains cash balances at various financial
institutions primarily located in the U.S. Accounts held at the
U.S. institutions are secured, up to certain limits, by the Federal
Deposit Insurance Corporation. At times, balances may exceed federally insured limits. The
Company has not experienced any
losses in such accounts. There is credit risk related to the
Company’s ability to collect on its accounts receivables from its
major customers. Management believes that the Company is not exposed to any significant credit risk
with respect to its cash and cash equivalent balances and accounts
receivables.
Litigation
The Company is party to litigation at the present time and
may become party to litigation in
the future. In general, litigation claims can be expensive, and
time consuming to bring or defend against and could result in
settlements or damages that could significantly affect financial
results. However, it is not
possible to predict the final resolution of any litigation to which
the Company is, or may be party to,
and the impact of certain of these matters on the Company’s
business, results of operations, and financial condition could be
material. At both March 31, 2020
and December 31, 2019, the Company
believed that existing litigation had no merit and was not likely that the Company would incur any
losses with respect to litigation.
Vendor Concentration
For the three months ended
March 31, 2020, the Company’s
direct selling segment made purchases from two vendors, Global
Health Labs, Inc., and Michael Schaffer, LLC., that individually
comprised more than 10% of total
segment purchases and in aggregate approximated 41% of total
segment purchases. For the three
months ended March 31, 2019, the
Company’s direct selling segment made purchases from two vendors,
Global Health Labs, Inc. and Icelandic Water Holdings, that
individually comprised more than 10% of total segment purchases and in
aggregate approximated 44% of total segment purchases.
For the three months ended
March 31, 2020, the Company’s
commercial coffee segment made purchases from two vendors, H&H
and StoneX Commodity Solutions, LLC, that individually comprised
more than 10% of total segment
purchases and in aggregate approximated 49% of total segment
purchases. For the three months
ended March 31, 2019, the Company’s
commercial coffee segment made purchases from one vendor, H&H,
that approximated 71% of total segment purchases.
For the three months ended
March 31, 2020, the Company’s
commercial hemp segment made purchases from two vendors,
BioProcessing Corp and Xtraction Services, Inc., that individually
comprised more than 10% of total
segment purchases and in aggregate approximated 64% of total
segment purchases. For the three
months ended March 31, 2019, the
Company’s commercial hemp segment made purchases from two vendors,
Labfirst Scientific and industrial and Xian Toption Instrument Co.,
LTD, that individually comprised more than 10% of total segment purchases and in
aggregate approximated 79% of total segment purchases.
Customer Concentration
For the three months ended
March 31, 2020, the Company’s
commercial coffee segment had four customers, Carnival Cruise
Lines, Rothfos Corporation, Super Store Industries and Topco
Associates, LLC, that individually comprised more than 10% of segment revenue and in aggregate
approximated 58% of total segment revenue. For the three months ended March 31, 2019, the Company’s commercial
coffee segment had one customer, H&H Export, that approximated
63% of total segment revenue.
At March 31, 2020 and December 31, 2019, CLR's accounts receivable
balance for customer related revenue by H&H Export was
approximately $8,707,000 of which the full amount was past due at
the corresponding periods. As a result, the Company reserved
$7,871,000 as bad debt related to the accounts receivable balances
for both periods, which was net of collections through December 31, 2020.
The Company has purchase obligations related to minimum future
purchase commitments for green coffee to be used in the Company’s
commercial coffee segment within its roasting operations. Each
individual contract requires the Company to purchase and take
delivery of certain quantities at agreed upon prices and delivery
dates. The contracts have minimum future purchase commitments
of approximately $8,957,000 at March 31,
2020. The contracts contain provisions whereby any delays
in taking delivery of the purchased product will result in
additional charges related to the extended warehousing of the
coffee product. The Company has not incurred fees however fees can average
approximately $0.01 per pound for every month of delay.
- 34-
For the three months ended
March 31, 2020, the Company’s
commercial hemp segment had two customers, Just Hemp, LLC and Vash
Holdings, LLC, that individually comprised more than 10% of segment revenue and in aggregate
approximated 41% of total segment revenue. For the three months ended March 31, 2019, the Company’s commercial hemp
segment had two customers, Air Spec, Inc. and Xtraction Services,
that individually comprised more than 10% of segment revenue and in aggregate
approximated 65% of total segment revenue.
Note 12. Segment and
Geographical Information
The Company operates in three segments: the direct selling
segment where products are offered through a global distribution
network of preferred customers and distributors, the commercial
coffee segment where roasted and green coffee bean products are
sold directly to businesses, and the commercial hemp segment
manufactures proprietary systems to provide end-to-end extraction
and processing that allow for the conversion of hemp feed stock
into hemp oil and hemp extracts.
The Company’s segments reflect the manner in which the business is
managed and how the Company allocates resources and assesses
performance. The Company’s chief operating decision maker is the
Chief Executive Officer. The Company’s chief operating decision
maker evaluates segment performance primarily based on revenue and
segment operating income (loss). The principal measures and factors
the Company considered in determining the number of reportable
segments were revenue, gross margin percentage, sales channel,
customer type and competitive risks.
The accounting policies of the segments are consistent with those
described in the summary of significant accounting policies.
Segment revenue excludes intercompany revenue eliminated in the
consolidation.
The following tables present selected financial information for
each segment (in thousands):
|
|
Three Months Ended
March 31,
|
|
|
|
2020
|
|
|
2019
|
|
|
|
(unaudited) |
|
|
(unaudited) |
|
Revenues
|
|
|
|
|
|
|
|
|
Direct selling
|
|
$ |
31,156 |
|
|
$ |
33,420 |
|
Commercial coffee
|
|
|
4,059 |
|
|
|
7,705 |
|
Commercial hemp
|
|
|
316 |
|
|
|
67 |
|
Total revenues
|
|
$ |
35,531 |
|
|
$ |
41,192 |
|
Gross profit (loss)
|
|
|
|
|
|
|
|
|
Direct selling
|
|
$ |
20,675 |
|
|
$ |
22,755 |
|
Commercial coffee
|
|
|
(564 |
)
|
|
|
4,067 |
|
Commercial hemp
|
|
|
(324 |
)
|
|
|
27 |
|
Total gross profit
|
|
$ |
19,787 |
|
|
$ |
26,849 |
|
Operating income (loss)
|
|
|
|
|
|
|
|
|
Direct selling
|
|
$ |
(2,642 |
)
|
|
$ |
(12,309 |
)
|
Commercial coffee
|
|
|
(1,771 |
)
|
|
|
884 |
|
Commercial hemp
|
|
|
(2,264 |
)
|
|
|
(516 |
)
|
Total operating loss
|
|
$ |
(6,677 |
)
|
|
$ |
(11,941 |
)
|
Net income (loss)
|
|
|
|
|
|
|
|
|
Direct selling
|
|
$ |
(2,618 |
)
|
|
$ |
(13,377 |
)
|
Commercial coffee
|
|
|
(895 |
)
|
|
|
1,633 |
|
Commercial hemp
|
|
|
(2,278 |
)
|
|
|
(516 |
)
|
Total net loss
|
|
$ |
(5,791 |
)
|
|
$ |
(12,260 |
)
|
Capital expenditures
|
|
|
|
|
|
|
|
|
Direct selling
|
|
$ |
156 |
|
|
$ |
17 |
|
Commercial coffee
|
|
|
346 |
|
|
|
2,572 |
|
Commercial hemp
|
|
|
606 |
|
|
|
1,384 |
|
Total capital expenditures
|
|
$ |
1,108 |
|
|
$ |
3,973 |
|
Capital expenditures acquired through acquisition
|
|
|
|
|
|
|
|
|
Direct selling
|
|
$ |
- |
|
|
$ |
- |
|
Commercial coffee
|
|
|
- |
|
|
|
- |
|
Commercial hemp
|
|
|
- |
|
|
|
1,133 |
|
Total capital expenditures acquired through acquisitions
|
|
$ |
- |
|
|
$ |
1,133 |
|
- 35-
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
|
|
(unaudited) |
|
|
|
|
Total assets
|
|
|
|
|
|
|
|
|
Direct selling
|
|
$ |
40,584 |
|
|
$ |
43,221 |
|
Commercial coffee
|
|
|
34,927 |
|
|
|
34,348 |
|
Commercial hemp
|
|
|
11,825 |
|
|
|
12,122 |
|
Total assets
|
|
$ |
87,336 |
|
|
$ |
89,691 |
|
Total net property and equipment assets located outside the U.S.
were approximately $7,671,000 and $7,787,000 at March 31, 2020 and December 31, 2019, respectively.
The Company conducts its operations primarily in the U.S. For the
three months ended March 31, 2020 and 2019, approximately 17% and 13%,
respectively, of the Company’s sales were derived from sales
outside the U.S.
The following table displays revenues attributable to the
geographic location of the customer (in thousands):
|
|
Three Months
Ended March 31,
|
|
|
|
2020
|
|
|
2019
|
|
|
|
(unaudited) |
|
|
(unaudited) |
|
Revenues
|
|
|
|
|
|
|
|
|
United States
|
|
$ |
29,599 |
|
|
$ |
35,782 |
|
International
|
|
|
5,932 |
|
|
|
5,410 |
|
Total revenues
|
|
$ |
35,531 |
|
|
$ |
41,192 |
|
Note 13. Subsequent
Events
Line of Credit
In January 2022, the Company
entered into the second amendment
to the Crestmark loan and security agreement which reduced the
maximum overall borrowing limit on the line of credit to
$3,000,000. Under the second
amendment to the Crestmark loan and security agreement, the line of
credit may not exceed an amount which is the lesser of
(a) $3,000,000 or (b) the sum of up (i) to 85% of the value of the
eligible accounts; plus, (ii) the lesser of $1,000,000 or 50% of
eligible inventory or 50% of the amount calculated in (i)
above.
In February 2022, the Company
received a notice of default related to the loan and security
agreement from Crestmark. The default includes the Company’s
failure to provide quarterly financial statements for the quarters
ended September 30, 2021 and
December 31, 2021, as set forth in
the loan agreement. As a result of this default, Crestmark has the
right to charge a higher rate, to accelerate the indebtedness, and
to enforce any other right or remedy set forth in the loan
agreement.
In April 2022, the Company entered
into a forbearance agreement with Crestmark. The forbearance
agreement provides that Crestmark agreed to forbear from collection
action under the loan documents until the termination date of
June 30, 2022, provided the Company
is in compliance with the terms of the forbearance agreement. At
the filing date of this Quarterly Report on Form 10-Q, the Company is not currently in compliance with the terms of
the forbearance agreement. On June 17,
2022, the balance of the line of credit was approximately
$1,718,000.
Daniel Mangless - Settlement Agreement
Effective February 2021, the
beneficial ownership in the Company’s common stock for Mr. Mangless
dropped below 5% to sole ownership
of 176,000 shares of common stock based on information contained in
a Schedule 13G filed with the SEC
in March 2021.
In April 2021, the Company entered
into a Settlement Agreement (the “Settlement Agreement”) by and
among the Company, CLR, and Daniel Mangless to settle all claims
related to a lawsuit filed by Mr. Mangless against the Company and
CLR in February 2021, for the
alleged breach by the Company and CLR of their obligations under
the Mangless Note and the Mangless Pledge and Security Agreement
(See Mangless v. Youngevity International, Inc. and CLR Roasters
LLC, Case No. 2021-CA-996-O
(Fla. Cir. Ct.)) (the “Lawsuit”). Pursuant to the Settlement
Agreement, Mr. Mangless has agreed to dismiss the lawsuit, with
prejudice within five days of the
Company making all of the payments required under the Settlement
Agreement.
Pursuant to the Settlement Agreement, the Company made a payment of
approximately $195,000 to Mr. Mangless in April 2021 and made payments of approximately
$102,000 per month to Mr. Mangless beginning in May 2021, and on every month thereafter
through and including January 2022.
In addition, pursuant to the Settlement Agreement, the Company
agreed to issue Mr. Mangless 1,000,000 shares of its common stock
(the “Settlement Shares”). The Company also agreed that following
the date the Company has completed the audit of its financial
statements for the years ended December
31, 2020, if it is then necessary to register the Settlement
Shares with the SEC to allow Mr. Mangless to resell the Settlement
Shares in the open market, to file a registration statement on Form
S-1 within 60 days after bringing its audit filings up
to date. The promissory note, including interest was paid, and the
shares were issued in accordance with the terms of the settlement
agreement.
- 36-
Finance Lease
In August 2020, the Company entered
into a lease for assorted CBD oil extraction equipment that
included processing equipment, modular buildings, assorted
laboratory equipment, refrigeration equipment with Varilease
Finance, Inc. (“VFI”). The value of the equipment at the lease date
was approximately $2,006,000. The monthly lease payments are
$79,000 over a period of 24 months,
with an advance payment of $79,000 to be applied to the last rental
payment date. At the filing date of this Quarterly Report on Form
10-Q, the VFI lease was in
default.
Small Business Administration – Paycheck
Protection Program Loan
In April 2020, the Company’s
three segments participated in “The
Coronavirus Aid, Relief, and Economic Security Act and the Paycheck
Protection Program due to losses caused by the COVID-19 pandemic. In April 2020, the Company received cash in the
aggregate of approximately $3,763,000 from qualified Small Business
Administration (“SBA”) lenders. Under the SBA loans, the Company
received $2,508,000 related to its direct selling segment, $633,000
related to its commercial coffee segment and $623,000 related to
its commercial hemp segment of which $61